Krzesinski, Jean-Marie, Scheen, André
L’intérêt pour de nouvelles associations antihypertensives très efficaces et, si possible, encore mieux tolérées est grand dans le domaine de l’hypertension artérielle, vu l’échec...
Anticorps monoclonaux en diabétologie : jusqu’au bout du rêve ? (2009)
Philips, Jean-Christophe, Keymeulen, B, Mathieu, C, Scheen, André
SUMMARY : Type 1 diabetes is characterized by the autoimmune- mediated destruction of the insulin-producing beta cells of the pancreatic islets of Langerhans. Several cells are potentially implicated...
Esser, Nathalie, Paquot, Nicolas, Scheen, André
Around 30 to 50% of obese subjects are “metabolically normal” (MHO) whereas numerous nonobese subjects are “metabolically abnormal”. The distribution and function of adipose deposits seem to...
Krzesinski, Jean-Marie, Scheen, André
Arterial hypertension is an important cardiovascular risk factor. The benefit drawn from decreasing and normalizing the blood pressure level is indisputable. The ACCOMPLISH study performed in...
Krzesinski, Jean-Marie, Scheen, André
Arterial hypertension is an important cardiovascular risk factor. The benefit drawn from decreasing and normalizing the blood pressure level is indisputable. The ACCOMPLISH study performed in...
"Metaboliquement obeses" sans exces de poids: un phenotype interpellant. (2009)
Obesity, especially abdominal obesity, is the main risk factor of metabolic syndrome. However, there are obviously non obese individuals who are metabolically abnormal and therefore exposed to an...
Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders. (2009)
Scheen, André, Paquot, Nicolas
Abdominal obesity is associated with numerous metabolic abnormalities, including insulin resistance, impaired glucose tolerance/type-2 diabetes, and atherogenic dyslipidaemia with low high-density...
The endocannabinoid system: a promising target for the management of type 2 diabetes. (2009)
Type 2 diabetes is closely related to abdominal obesity and is generally associated with other cardiometabolic risk factors, resulting in a high incidence of cardiovascular complications. Several...
Sujets obèses sans anomalies métaboliques (2009)
Esser, Nathalie, Scheen, André
Obesity, especially abdominal obesity, is the main risk factor of metabolic syndrome. However, there are obviously non obese individuals who are metabolically abnormal and therefore exposed to an...
Delanaye, Pierre, Cavalier, Etienne, Radermecker, Régis, Paquot, Nicolas, Depas, Gisèle, Chapelle, J-P, ...
Background: Patients with anorexia nervosa (AN) are at high risk of renal failure. Glomerular filtration rate (GFR) is overestimated when estimated by the creatinine-based equations. We have studied...
De Flines, Jenny, Radermecker, Régis, Jandrain, Bernard, Scheen, André
The diabetic patient, when type 2 diabetes is newly diagnosed, raises a therapeutic problem commonly observed in clinical practice, which is more complex than expected at first glance. The physician...
Scheen, André, Paquot, Nicolas
Vildagliptin (Galvus) is a selective inhibitor of dipeptidylpeptidase-4, an enzyme involved in the metabolism of glucagon-like peptide-1 (GLP-1) secreted by L cells of the intestine. It potentiates...
Rosiglitazone: to be or not to be? (2009)
The original publication is available at www.springerlink.com
Philips, Jean-Christophe, Marchand, Monique, Scheen, André
BACKGROUND: To evaluate changes in pulse pressure (PP) and markers of cardiovascular autonomic neuropathy (CAN) according to duration of type 1 diabetes mellitus (T1DM). METHODS: This cross-sectional...
Nomenclature internationale des differents types d'anticorps monoclonaux. (2009)
Significant advances in the development of monoclonal antibodies ("mabs") have been acknowledged during the last two decades. Successive developments led to the marketing of murine antibodies...
Nouvelles avancees dans l'utilisation des anticorps monoclonaux en therapeutique. (2009)
New major advances may be expected in a near future regarding the use of monoclonal antibodies (mAb), mainly thanks to the remarkable progress in biotechnology and the better knowledge of cellular...
Philips, Jean-Christophe, Scheen, André
Insulin detemir (Levemir) is a soluble human insulin analogue acylated with a 14-carbon fatty acid, which reversibly binds to albumin, thereby providing a more prolonged metabolic effect with lower...
Legrand, Victor, Scheen, André, Nyssen, Astrid
Various systemic pharmacological approaches have been evaluated to reduce the risk of restenosis after coronary angioplasty, with or without stent, in the general population and in diabetic patients...
Nyssen, Astrid, Legrand, Victor, Scheen, André
Différentes approches pharmacologiques systémiques ont été testées pour réduire le risque de resténose et de complications après angioplastie coronaire, avec ou sans stent, objectif...
Radermecker, Régis, Renard, Emilie, Scheen, André
The purification of animal insulin preparations and the use of human recombinant insulin have markedly reduced the incidence, but not completely suppressed, the development of anti-insulin antibodies...
Quelle est la nouvelle donne pour soigner les patients diabétiques de type 2 ? (2009)
Scheen, André, Paquot, Nicolas
Le traitement du diabète de type 2 est une tâche plus difficile qu’il n’y paraît en raison de la complexité de la maladie du point de vue physiopathologique, de l’adhésion imparfaite du...
Scheen, André, Krzesinski, Jean-Marie
Coveram is a new fixed combination of an angiotensin converting enzyme inhibitor, perindopril, and a calcium antagonist, amlodipine. This new medication is indicated for the treatment of arterial...
Bases immunologiques a la comprehension du concept d'anticorps monoclonal. (2009)
Moutschen, Michel, Scheen, André
Antibodies (Ab) are molecules with dual functions: on the one hand, they bind to antigens (Ag) through their variable regions (Fab, "Fragment antigen binding"), located at one of their extremities;...
Anticorps monoclonaux en diabetologie: jusqu'au bout du reve? (2009)
Philips, Jean-Christophe, Keymeulen, B, Mathieu, C, Scheen, André
Type 1 diabetes is characterized by the autoimmune-mediated destruction of the insulin-producing beta cells of the pancreatic islets of Langerhans. Several cells are potentially implicated in the...
Delanaye, Pierre, Cavalier, Etienne, Rorive, Marcelle, Radermecker, Régis, Scheen, André, Krzesinski, Jean-Marie
World Congress of Nephrology
High levels of high-sensitivity C-reactive protein (hs-CRP) are an independent cardiovascular marker, which may be reduced by statin therapy. JUPITER is a randomised clinical trial that compares the...
Traitements neuroleptiques et troubles métaboliques (2008)
Scheen, André, Van Winkel, R, De Hert, Marc
Les neuroleptiques, en particulier les antipsychotiques atypiques ou de seconde génération, sont associés à des troubles métaboliques dont un gain pondéral, parfois majeur, un syndrome...
RÉSUMÉ : Le patient obèse souffrant de gonarthrose, d’hypertension artérielle, de diabète de type 2, d’hyperuricémie, de dyslipidémie mixte et d’insuffisance rénale modérée est...
Nyssen, Astrid, Legrand, Victor, Scheen, André
The diabetic patient is at high risk of coronary heart disease. He/she can benefit of revascularisation procedures, even if he/she is exposed to a higher incidence of complications after a coronary...
RÉSUMÉ : Le patient obèse souffrant de gonarthrose, d’hypertension artérielle, de diabète de type 2, d’hyperuricémie, de dyslipidémie mixte et d’insuffisance rénale modérée est...
Le médicament du mois. L'insuline (2008)
Radermecker, Régis, Scheen, André
L’insuline asparte biphasique NovoMix® 50 est une nouvelle insuline prémixée comprenant 50 % de l’analogue ultra-rapide asparte et 50 % d’insuline asparte protaminée cristallisée. Cette...
Instabilité glycémique et anticorps anti-insuline (2008)
Renard, E, Radermecker, Régis, Scheen, André
L’instabilité glycémique est courante chez les malades traités par insuline et invalidante en raison des hypoglycémies répétées, soudaines, parfois sévères. Les formulations d’insuline...
Radermecker, Régis, Philips, Jean-Christophe, Jandrain, Bernard, Paquot, Nicolas, Scheen, André
Type 2 diabetes is associated with a high risk of complications, essentially macrovascular events. Surprisingly, the effect of improved glucose control on coronary and cerebrovascular complications...
[How I treat... by optimizing the blockade of the renin-angiotensin-aldosterone system] (2008)
Schleich, FLorence, Krzesinski, Jean-Marie, Pierard, Luc, Scheen, André
The blockade of the renin-angiotensin-aldosterone system (RAAS) has been shown to be useful, or even mandatory, in the management of arterial hypertension, congestive heart failure, post-myocardial...
Ruilope, Luis M, Despres, Jean-Pierre, Scheen, André, Pi-Sunyer, Xavier, Mancia, Guiseppe, Zanchetti, Alberto, ...
OBJECTIVE: Rimonabant, the first selective cannabinoid type 1 (CB1) receptor blocker, has been shown to improve multiple cardiometabolic risk factors in overweight/obese patients. This analysis...
Philips, Jean-Christophe, Marchand, Monique, Scheen, André
OBJECTIVE: To evaluate pulse pressure changes according to duration of type 1 diabetes and to assess the influence of posture. RESEARCH DESIGN AND METHODS: We performed continuous measurement of...
Scheen, André, Krzesinski, Jean-Marie
ONTARGET ("ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial") compared the angiotensin converting enzyme inhibitor ramipril (10 mg/day), the angiotensin-receptor...
Exenatide (Byetta) is a synthetic derivative of exendin-4 and an agonist of receptors of glucagon-like peptide-1 (GLP-1). It is resistant to the rapid inactivation by dipeptidylpeptidase-4 and acts...
Risque anesthesique lie a une neuropathie autonome cardiaque chez le patient diabetique. (2008)
Van Cauwenberge, Isabelle, Philips, Jean-Christophe, Scheen, André
Cardiac autonomic neuropathy is an underestimated complication among diabetic patients. It affects both the sympathetic and parasympathetic systems and is often associated with other, autonomic or...
Wallemacq, Caroline, Scheen, André
Coronary artery disease is the major cause of mortality of type 2 diabetic subjects. Its early diagnosis to prevent progression and clinical events has intuitive appeal. Somehow, rationale for...
Do thiazolidinediones increase the risk of congestive heart failure and cardiovascular death? (2008)
Van Winkel, Ruud, Van Os, Jim, Celic, Ivan, Van Eyck, Dominique, Wampers, Martien, Scheen, André, ...
OBJECTIVE: Unconfounded differences in inherent vulnerability to metabolic disturbance may be hypothesized for different diagnostic groups with severe mental illness. METHOD: A naturalistic cohort of...
Van Winkel, Ruud, De Hert, Marc, Wampers, Martien, Van Eyck, Dominique, Hanssens, Linda, Scheen, André, ...
OBJECTIVE: To investigate 3-month changes in glucose metabolism in a naturalistic sample of patients with schizophrenia newly started on or switched to specific atypical antipsychotic medication...
The future of obesity: new drugs versus lifestyle interventions. (2008)
BACKGROUND: Obesity causes serious medical complications and impairs quality of life. However, its management remains challenging. OBJECTIVE: To assist health professionals who counsel patients who...
Wallemacq, Caroline, Scheen, André
La maladie coronarienne est la première cause de mortalité des sujets diabétiques de type 2. Intuitivement, son dépistage précoce devrait être bénéfique dans une optique de prévention....
Legrand, Delphine, Krzesinski, Jean-Marie, Scheen, André
The blockade of the renin-angiotensin-aldosterone system (RAAS) is helpful in the management of arterial hypertension, congestive heart failure, post-myocardial infarction and diabetic nephropathy....
Nyssen, Astrid, Legrand, Victor, Scheen, André
Coronary drug-eluting stents (DES) are increasingly used in interventional cardiology. Stents coated with pharmacological substances such as sirolimus or paclitaxel, capable of reducing endothelial...
L'etude clinique du mois. United Kingdom Prospective Diabetes Study": 10 ans plus tard." (2008)
Scheen, André, Paquot, Nicolas, Lefebvre, Pierre
A 10-year post-trial monitoring of patients with newly diagnosed type 2 diabetes randomised in the "United Kingdom Prospective Diabetes Study" (UKPDS) demonstrated a continued reduction in...
New therapeutic approaches in type 2 diabetes. (2008)
Type 2 diabetes is a progressive chronic disease resulting from a dynamic interaction between defects in insulin secretion and insulin action. New molecules have recently been launched and many...
Medications in the kidney. (2008)
Patients with chronic kidney disease (CKD) constitute a population at high risk for adverse drug reactions and/or drug-drug interactions. Renal dysfunction-induced pathophysiological changes may...
Comment je traite ... en optimisant le blocage du système rénine-angiotensine-aldostérone (2008)
Schleich, F., Krzesinski, Jean-Marie, Pierard, Luc, Scheen, André
The blockade of the renin-angiotensin-aldosterone system (RAAS) has been shown to be useful, or even mandatory, in the management of arterial hypertension, congestive heart failure, post-myocardial...
Endoprotheses coronaires pharmaco-actives chez les patients diabetiques. (2008)
Nyssen, Astrid, Legrand, Victor, Scheen, André
In diabetic patients, the use of drug-eluting stents (paclitaxel-PES or sirolimus-SES) reduces the risk of restenosis as compared to bare-metal stents. However, the risk of (very) late thrombosis is...
Hanssens, L, Scheen, André, Van Winkel, R, Van Eyck, D, Reginster, Jean-Yves, De Hert, M
Schizophrenia is associated with an increased risk of metabolic disorders such as diabetes, dyslipidaemia and the metabolic syndrome. The prevalence of type 2 diabetes in schizophrenic patients is at...
Le système endocannabinoïde dans le cerveau... et ailleurs (2008)
Scheen, André, Seutin, Vincent, Van Gaal, L F
The endocannabinoid system is a complex system with endogenous ligands, synthesis and transport processes, specific receptors (CB1 and CB2) and intracellular degrading enzymes. It is widely...
Des statines pour le cerveau. Le point en 2008. (2008)
Scheen, André, Radermecker, Régis, Sadzot, Bernard
Statins are essential drugs for the prevention of coronary artery disease. There is now evidence that they can also prevent ischemic stroke. The protective effect is related to the reduction in total...
Radermecker, Régis, Philips, Jean-Christophe, Jandrain, Bernard, Paquot, Nicolas, Lefebvre, Pierre, Scheen, André
Glucose is almost the only energy substrate for the brain. Such glucose dependence explains why any large variation of plasma glucose levels could lead to cerebral dysfunction, which may be severe...
Sitagliptin (Januvia) is the first selective antagonist of dipeptidylpeptidase-4, an enzyme that degrades glucagon-like peptide-1 (GLP-1). This hormone is mainly secreted by ileal L cells and this...
Rimonabant (Acomplia) is the first selective CB1 receptor blocker of the endocannabinoid system. Clinical trials showed that, compared to placebo, rimonabant 20 mg/ day consistently increases weight...
Le medicament du mois. L'aliskiren (Rasilez), inhibiteur direct de la renine. (2008)
Scheen, André, Pierard, Luc, Krzesinski, Jean-Marie
Aliskiren (Rasilez) is the first oral renin inhibitor. Its present indication is essential hypertension, as monotherapy or in combination with other antihypertensive agents (diuretic, calcium...
L'etude clinique du mois. "United Kingdom Prospective Diabetes Study": 10 ans plus tard. (2008)
Scheen, André, Paquot, Nicolas, Lefebvre, Pierre
A 10-year post-trial monitoring of patients with newly diagnosed type 2 diabetes randomised in the "United Kingdom Prospective Diabetes Study" (UKPDS) demonstrated a continued reduction in...
Van Gaal, Luc F, Scheen, André, Rissanen, Aila M, Rossner, Stephan, Hanotin, Corinne, Ziegler, Olivier
AIMS: Rimonabant, the first selective cannabinoid type 1 receptor blocker, has been shown to produce weight loss and improvements in several cardiometabolic risk factors over 1 year. We report the 2...
De Hert, Marc, Schreurs, Vincent, Sweers, Kim, Van Eyck, Dominique, Hanssens, Linda, Sinko, Sebastjan, ...
The presence of the metabolic syndrome (MetS) is an important risk factor for cardiovascular disease and diabetes. There are limited data on the prevalence of MetS in patients with schizophrenia at...
Van Gaal, Luc, Pi-Sunyer, Xavier, Despres, Jean-Pierre, McCarthy, Christine, Scheen, André
OBJECTIVE: To better define the efficacy and safety of rimonabant, the first selective cannabinoid type 1 (CB(1)) receptor antagonist, in a large population of overweight and obese patients using...
Rimonabant, the first selective CB(1) receptor antagonist in clinical use, has been extensively investigated in the Rimonabant in Obesity (RIO) programme, comprising four 1-2 year placebo-controlled...
Le syndrome métabolique, physiopathologie et traitement (2008)
Mise à jour du chapitre paru en 2006
SUMMARY : High levels of high-sensitivity C-reactive protein (hs-CRP) are an independent cardiovascular marker, which may be reduced by statin therapy. JUPITER is a randomised clinical trial that...
Efficacy and safety of the weight-loss drug rimonabant. (2008)
Despres, Jean-Pierre, Van Gaal, Luc, Pi-Sunyer, Xavier, Scheen, André
Scheen, André, Paquot, Nicolas, Van Gaal, Luc F
Endocannabinoid system is overactivated in individuals with abdominal obesity. CBI receptors, first individualized in the brain, are also expressed in the adipocyte, the skeletal muscle, the liver,...
Inhibitors of cannabinoid receptors and glucose metabolism. (2008)
Scheen, André, Paquot, Nicolas
PURPOSE OF REVIEW: Abdominal obesity is closely related to type 2 diabetes and overactivity of the endocannabinoid system. The present review aims at evaluating the role of endocannabinoid system in...
Debacker, Nathalie, Nobels, F, Vandenberghe, H, Van Crombrugge, P, Scheen, André, Van Casteren, V
AIMS: To describe the IQED, a quality-assurance system started in 2001 in Belgian hospital-based multidisciplinary diabetes centres, and its effects on the quality of care. METHODS: The study was...
Hanssens, Linda, Van Winkel, Ruud, Wampers, Martien, Van Eyck, Dominique, Scheen, André, Reginster, Jean-Yves, ...
BACKGROUND: In recent years, several studies showed increased rates of hyperglycaemia, diabetes, dyslipidemia, metabolic syndrome as well as cardiovascular disease in schizophrenic patients. The...
Van Winkel, Ruud, De Hert, Marc, Van Eyck, Dominique, Hanssens, Linda, Wampers, Martien, Scheen, André, ...
OBJECTIVES: The presence of metabolic abnormalities is an important risk factor for cardiovascular disease and diabetes. There are limited data on the prevalence of the metabolic abnormalities in...
Ruilope, Luis M, Despres, Jean-Pierre, Scheen, André, Pi-Sunyer, Xavier, Mancia, Guiseppe, Zanchetti, Alberto, ...
OBJECTIVE: Rimonabant, the first selective cannabinoid type 1 (CB1) receptor blocker, has been shown to improve multiple cardiometabolic risk factors in overweight/obese patients. This analysis...
Cystatin C or Creatinine for Detection of Stage 3 Chronic Kidney Disease in Anorexia Nervosa. (2008)
Delanaye, Pierre, Cavalier, Etienne, Radermecker, Régis, Paquot, Nicolas, Depas, Gisèle, Chapelle, Jean-Paul, ...
Background: Patients with anorexia nervosa (AN) are at a high risk of renal failure. Chronic kidney disease (CKD) is often missed in these patients because the serum creatinine is a poor marker of...
Ducobu, Jean, Scheen, André, Van Gaal, Luc, Velkeniers, Brigitte, Hermans, Michel
The demographics of dyslipidaemia have changed towards a more complex atherogenic dyslipidaemia involving increased levels of LDL-C, in particular highly atherogenic small dense particles,...
Beck, Emmanuel, Paquot, Nicolas, Scheen, André
Metabolically obese normal-weight (MONW) individuals are frequently not detected because of a falsely reassuring body weight. However, they have most of the metabolic syndrome markers known to be...
Beck, Emmanuel, Paquot, Nicolas, Scheen, André
Obesity, particularly abdominal obesity, is the main risk factor for metabolic syndrome. However, some non-obese individuals are metabolically abnormal and therefore probably have an increased risk...
Hanssens, Linda, Van Winkel, Ruud, Wampers, Martien, Van Eyck, Dominique, Scheen, André, Reginster, Jean-Yves, ...
BACKGROUND: In recent years, several studies showed increased rates of hyperglycaemia, diabetes, dyslipidemia, metabolic syndrome as well as cardiovascular disease in schizophrenic patients. The...
A case series: Evaluation of the metabolic safety of aripiprazole (2007)
De Hert, M, Hanssens, L, Van Winkel, R, Wampers, M, Van Eyck, D, Scheen, André, ...
Metabolic abnormalities occur frequently in patients treated with antipsychotics and are of growing concern to clinicians. This study sought to determine whether antipsychotic-associated metabolic...
Krzesinski, Jean-Marie, Scheen, André
Hypertension is a common treatable risk factor for cardiovascular disease. Even when identified and treated, most patients with hypertension do not get to blood pressure goal and they often need at...
Le glucagon-like peptide-1 (GLP-1), nouvelle cible dans le traitement du diabete de type 2. (2007)
Glucagon-like peptide-1 (GLP-1) is a gut hormone secreted in response to the ingestion of a meal. It exerts various favourable metabolic effects among which a glucose-dependent stimulation of insulin...
Rimonabant (Acomplia) is the first selective CB1 receptor blocker of the endocannabinoid system. It has been evaluated in the RIO ("Rimonabant In Obesity and related disorders") programme including...
ADOPT ("A Diabetes Outcome Progression Trial") is a double-blind, controlled clinical trial that aims at assessing the efficacy of rosiglitazone, as compared to metformin or glibenclamide, in...
Scheen, André, Krzesinski, Jean-Marie
The controlled ADVANCE trial compared the incidence of major macrovascular and microvascular complications in 5,569 type 2 diabetic patients randomised to a fixed combination of perindopril and...
Legrand, Delphine, Scheen, André
Aspirin is considered the gold standard antiplatelet therapy for primary and secondary prevention of cardiovascular (CV) disease. However, it appears less protective in diabetic patients than in the...
La consommation reguliere de cafe reduirait le risque de diabete de type 2. (2007)
Legrand, Delphine, Scheen, André
The prevention of type 2 diabetes has become a major public health objective. Cross-sectional studies have shown a lower prevalence of type 2 diabetes among coffee drinkers. The present article...
Radermecker, Régis, Pierard, Gérald, Scheen, André
Management of diabetes mellitus can be responsible for cutaneous adverse events. For example, lipoatrophy or lipohypertrophy can develop at the site of insulin injections. Lipohypertrophy remains a...
Le medicament du mois. Combinaison fixe ezetimibe/simvastatine (Inegy). (2007)
Scheen, André, Radermecker, Régis
Inegy, recently launched by Merck Sharp & Dohme and Schering Plough, is a fixed combination of simvastatin, which inhibits hepatic cholesterol synthesis, and ezetimibe, which selectively inhibits the...
Le point sur la controverse a propos de la rosiglitazone. (2007)
Scheen, André, De Flines, Jenny, Paquot, Nicolas
The present article aims at summarizing the recent controversy about rosiglitazone (Avandia), an insulin sensitizer used as oral antidiabetic agent in the treatment of type 2 diabetes. We will...
Actualites therapeutiques dans le domaine de l'obesite. (2007)
Rorive, Marcelle, De Flines, Jenny, Paquot, Nicolas, De Roover, Arnaud, Scheen, André
The management of an obese patient aims not only at obtaining a durable weight loss, but also at attenuating various associated risk factors. This latter objective may already be obtained with a...
Actualites therapeutiques en lipidologie. (2007)
Scheen, André, Radermecker, Régis, De Flines, Jenny, Ducobu, J
Clinical lipidology has gained its recognition with the publication of numerous clinical trials since the 4S study in 1994. Since that time statins have fully confirmed their promises and play now a...
Insuffisance cardiaque et diabete de type 2: une relation a double sens. (2007)
De Flines, Jenny, Scheen, André
The present article analyses the intimate relationship between diabetes mellitus and congestive heart failure. This relationship is indeed "bidirectional". On the one hand, it is well known that...
Abnormal glucose metabolism in patients treated with antipsychotics. (2007)
Second-generation (atypical) antipsychotic medications are of great benefit to a wide variety of people with psychiatric disorders, especially patients with schizophrenia. However, one constellation...
Cannabinoid-1 receptor antagonists in type-2 diabetes. (2007)
Type-2 diabetes is closely related to abdominal obesity and is generally associated with other cardiometabolic risk factors, resulting in a risk of major cardiovascular disease. Several animal and...
Les incretinomimetiques et incretinopotentiateurs dans le traitement du diabete de type 2. (2007)
Scheen, André, Radermecker, Régis, Philips, Jean-Christophe, Paquot, Nicolas
Glucagon-like peptide-1 (GLP-1) is a gut hormone secreted in response to a meal ingestion, which is rapidly degraded by a specific enzyme, dipeptidylpeptidase-4 (DPP-4). It enhances insulin secretion...
Existe-t-il une "memoire therapeutique" en prevention cardiovasculaire? (2007)
The prevention of type 2 diabetes and of cardiovascular diseases is a major public health objective. Obviously life-style changes play a major role in this strategy. The Finnish Prevention Study...
Puig, Juan Garcia, Marre, Michel, Kokot, Franciszek, Fernandez, Margarita, Jermendy, Gyorgy, Opie, Lionel, ...
BACKGROUND: Blood pressure control is the main influential variable in reducing microalbuminuria in patients with type 2 diabetes. In this subanalysis of the Natrilix SR versus Enalapril Study in...
Le diabete: de la connaissance clinique a la preoccupation de sante publique. (2007)
Diabetes mellitus is a chronic disease whose prevalence is increasing worldwide. It remains associated with a high risk of severe complications, essentially micro- and macro-vascular complications....
Evaluation de l'insulinosecretion et de l'insulinosensibilite (2007)
Insulin secretion and insulin sensitivity interact in concert to maintain glucose homeostasis. Various pathologies, especially type 2 diabetes, are characterized by defects in secretion and/or action...
This review describes the current knowledge on drug-drug and food-drug interactions with repaglinide and nateglinide. These two meglitinide derivatives, commonly called glinides, have been developed...
Glitazones et insuffisance cardiaque: resultats des etudes PROactive, ADOPT, DREAM et RECORD. (2007)
De Flines, Jenny, Scheen, André
Thiazolidinediones (TZDs) are used as insulin sensitizers in the treatment of type 2 diabetes, but are associated with an increased risk of congestive heart failure (CHF). The odds ratio of ICC was...
Van Winkel, R, De Hert, M, Van Eyck, D, Hanssens, L, Wampers, M, Scheen, André, ...
Objective: To assess the diagnostic properties of 2 different screening guidelines for the detection of diabetes in patients diagnosed with schizophrenia. Method: Over a 2-year period (November...
A cross-sectional study of adiponectin in patients with schizophrenia (2006)
Hanssens, L, De Hert, M, Van Eyck, D, Wampers, M, Scheen, André, Peuskens, J
Evaluation of the metabolic safety of aripiprazole (2006)
De Hert, M, Van Eyck, D, Hanssens, L, Wampers, M, Scheen, André, Peuskens, J
De Hert, Marc, Van Eyck, Dominique, Hanssens, Linda, Peuskens, Hendrik, Thys, Erik, Wampers, Martien, ...
Objective. - A recent consensus conference has proposed guidelines for the monitoring for diabetes in patients with schizophrenia and also identifies the need of long-term prospective studies....
De Hert, Marc A., Van Winkel, Ruud, Van Eyck, Dominique, Hanssens, Linda, Wampers, Martien, Scheen, André, ...
The presence of the metabolic syndrome is an important risk factor for cardiovascular disease and diabetes. There are limited data on the prevalence of the metabolic syndrome in European patients...
A cross-sectional study of adiponectin in patients with schizophrenia (2006)
Hanssens, L, De Hert, M, Van Eyck, D, Wampers, M, Scheen, André, Peuskens, J
Effects of aripiprazole on serum lipids, a comparison with patients started on statin (2006)
Hanssens, L, De Hert, M, Van Eyck, D, Wampers, M, Scheen, André, Peuskens, J
Evaluation of the metabolic safety of aripiprazole (2006)
De Hert, M, Van Eyck, D, Hanssens, L, Wampers, M, Scheen, André, Peuskens, J
Statin therapy among schizophrenia patients with dyslipidemia (2006)
Wampers, M, De Hert, M, Hanssens, L, Van Eck, D, Scheen, André, Peuskens, J
Insulin Detemir in the Treatment of Type 1 and Type 2 Diabetes (2006)
Insulin detemir is a soluble long-acting human insulin analogue at neutral pH with a unique mechanism of action. Following subcutaneous injection, insulin detemir binds to albumin via fatty acid...
Innover par l'EBM: glossaire initiatique aux recherches cliniques. (2006)
Pierard, Gérald, Scheen, André
We present a glossary of terms frequently used in medico-scientific studies.
Effect of rimonabant on quality of life in overweight/obese patients (2006)
Kolotkin, RL, Crosby, RD, Scheen, André, Golay, A, Despres, JP
DREAM ("Diabetes Reduction Assessment with ramipril and rosiglitazone Medication") is a double-blind randomised placebo-controlled clinical trial with a 2-by-2 factorial design aiming to study the...
L'aspirine en prevention primaire des maladies cardio-vasculaires chez le patient diabetique. (2006)
Legrand, Delphine, Scheen, André
Acetylsalicylic acid (aspirin) is widely used as antiplatelet therapy for the primary and secondary prevention of cardiovascular diseases. However, the effects appear to be different according to the...
The CHARISMA ("Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance") trial compared the effects of a dual antiplatelet therapy with clopidogrel plus low...
Cost related to insulin therapy is markedly increasing in Belgium, as in other Eucopean countries. In the present paper, we will briefly analyze the main reasons for such aa increase, integrate such...
Interactions medicamenteuses: de la theorie a la pratique. (2006)
Pharmacotherapy becomes increasingly complex and therapeutic targets are more and more ambitious for both care and prevention. Therefore, polypharmacy is frequent, which exposes the patient to a high...
Radermecker, Régis, Scheen, André
Sulfonylureas still have a key place in the treatment of type 2 diabetes, especially those of the last generation. This article describes the results of a post-marketing study (RECORD, Routine...
Conseils pour une meilleure prescription medicamenteuse. (2006)
Scheen, André, Parada, A, Giet, Didier
The prescription of a pharmacological agent concludes most medical visits. The rational basis of drug prescription by the physician relies on numerous pharmacodynamic, pharmacokinetic, pragmatic and...
ASTEROID is a prospective, open-label blinded end-points trial aiming to assess whether very intensive statin therapy with rosuvastatin 40 mg/day could regress coronary atherosclerosis as determined...
The comparison of two therapeutic interventions requires the use of endpoints in randomized clinical trials, which supports evidence-based medicine. It is preferable to consider hard endpoints, such...
The IDEAL ("Incremental Decrease in End Points Through Aggressive Lipid Lowering") study compared the effects of two strategies of lipid lowering on the risk of cardiovascular disease among patients...
Comment j'explore...le syndrome metabolique par sa nouvelle definition dite de "consensus". (2006)
Scheen, André, Luyckx, Françoise, Lefebvre, Pierre
The International Diabetes Federation recently proposed a so-called consensus definition of metabolic syndrome. According to this new definition, a subject has the metabolic syndrome if he/she has...
Innover par l'EBM: glossaire initiatique aux recherches cliniques. (2006)
Pierard, Gérald, Scheen, André
We present a glossary of terms frequently used in medico-scientific studies.
De Hert, Marc, Kalnicka, Dita, Van Winkel, Ruud, Wampers, Martien, Hanssens, Linda, Van Eyck, Dominique, ...
BACKGROUND: Mortality rates in patients with schizophrenia are double compared to those in the general population, with cardiovascular disease causing 50% of the excess. Lowering low-density...
Van Winkel, Ruud, De Hert, Marc, Van Eyck, Dominique, Hanssens, Linda, Wampers, Martien, Scheen, André, ...
OBJECTIVE: To assess the diagnostic properties of 2 different screening guidelines for the detection of diabetes in patients diagnosed with schizophrenia. METHOD: Over a 2-year period (November...
Radermecker, Régis, Scheen, André
The inhibition of cholesterol synthesis by a statin enhances intestinal absorption of both cholesterol and various phytosterols. The atherogenic role of phytosterols, well proven in...
Le diabete de type 1 et la maladie coeliaque. (2006)
Mathieu, Sandrine, Stassen, A, Paquot, Nicolas, Scheen, André
Celiac disease is more prevalent in type 1 diabetic patients than in the general population. The exact reason for this association remains unknown. Two hypotheses are taken into consideration: either...
La place des micronutriments en medecine. (2006)
Paquot, Nicolas, Scheen, André
Adequate micronutrient intake throughout life course is essential for the maintenance of health. Micronutrients are necessary for the maintenance of intermediary metabolism, play a crucial role as...
De Hert, M, Van Winkel, R, Van Eyck, D, Hanssens, L, Wampers, M, Scheen, André, ...
BACKGROUND: Patients with schizophrenia are at high risk of developing metabolic abnormalities. METHOD: A prospective study focusing on metabolic disturbances in patients with schizophrenia,...
Aspirin and clopidogrel resistance in patients with diabetes mellitus. (2006)
Scheen, André, Legrand, Delphine
published in European Heart Journal
Quelle place pour la prevention cardio-vasculaire par statine chez les personnes agees? (2006)
Petermans, Jean, Laperche, J, Scheen, André
Cardiovascular prevention should only be considered if the treatment reduces the incidence of coronary and cerebrovascular events and death. In elderly people, such treatment should also, and most...
Scheen, André, Van Gaal, L G, Despres, J P, Pi-Sunyer, X, Golay, A, Hanotin, C
RIO (Rimonabant In Obesity and related disorders) is a large phase 3 programme (>6600 patients) evaluating the efficacy and safety of rimonabant (5 or 20 mg/day), a CBI receptor antagonist of...
Hanssens, Linda, De Hert, Marc, Van Eyck, Dominique, Wampers, Martien, Scheen, André, Peuskens, Joseph
Legrand, Delphine, Scheen, André
Diabetes mellitus markedly increases the risk of cardiovascular diseases, with an especially elevated relative risk among women. Aspirin prescription is mandatory in secondary prevention, even if the...
Scheen, André, Finer, Nick, Hollander, Priscilla, Jensen, Michael D, Van Gaal, Luc F
BACKGROUND: Rimonabant, a selective cannabinoid type 1 receptor blocker, reduces bodyweight and improves cardiovascular and metabolic risk factors in non-diabetic overweight or obese patients. The...
Philips, Jean-Christophe, Marchand, Monique, Weekers, Laurent, Scheen, André
Diabetes mellitus and arterial pulse pressure (PP) are two independent cardiovascular risk factors. This cross-sectional study investigated the influence of diabetes duration on PP in type 1 diabetic...
Krzesinski, Jean-Marie, Montrieux, Christian, Scheen, André
Inhibitors of the renin-angiotensin system have proved their great value in secondary prevention trials for cardiovascular or renal complications. In favour of the preferred use of angiotensin...
Diabete sucre et decompensation cardiaque: specificites ethiopathogeniques et therapeutiques. (2006)
De Flines, Jenny, Scheen, André
Diabetes mellitus increases by 2.5 to 5 the relative risk of congestive heart failure. Besides the classical risk factors of congestive heart failure such as obesity, arterial hypertension and...
La prescription medicamenteuse chez la personne agee: que devonsnous savoir? (2006)
Wotquenne, Pol, Petermans, Jean, Scheen, André
Because of the increasing longevity of the population, a growing number of very old people are exposed to medications. Drug therapy in this population is difficult because of our lack of knowledge....
Dormandy, John A., Charbonnel, Bernard, Eckland, David J. A., Erdmann, Erland, Massi-Benedetti, Massimo, Kmoules, Ian K., ...
Background Patients with type 2 diabetes are at high risk of fatal and non-fatal myocardial infarction and stroke. There is indirect evidence that agonists of peroxisome proliferator-activated...
Six-month incidence of diabetes among schizophrenic patients in Belgium (2005)
Hanssens, L, De Hert, M, Van Eyck, D, Wampers, M, Scheen, André, Peuskens, J
Belgian consensus on metabolic problems associated with atypical antipsychotics (2005)
De Nayer, A, De Hert, M, Scheen, André, Van Gaal, L, Peuskens, J
A workshop was convened by a panel of psychiatrists, diabetologists and pharmacists from major Belgian hospitals to review the latest information relating to the risks with second-generation...
La place de la transplantation pancreatique dans le traitement du diabete (2005)
De Roover, Arnaud, Detry, Olivier, Coimbra Marques, Carla, Bonvoisin, Catherine, Beaujean, Marianne, Krzesinski, Jean-Marie, ...
Pancreas transplantation has now become an established option in the treatment of diabetic complications. It normalizes glucose metabolism, prevents, stabilizes and improves the evolution of...
Complications cutanées de l'insulinothérapie un problème iatrogène sur le déclin. (2005)
Pierard, Claudine, Hermanns, Trinh, Scheen, André, Pierard, Gérald
Insulin therapy is increasingly used. Hopefully, its complications are steadily decreasing in incidence since the introduction of new generations of insulin. The main cutaneous side effects were...
Radermecker, Régis, Scheen, André
FIELD ("Fenofibrate Intervention and Events Lowering in Diabetes") study compared the incidence of coronary and cardiovascular events in 4895 patients with type 2 diabetes treated with fenofibrate...
Scheen, André, Lefebvre, Pierre
PROactive is a prospective, randomised controlled trial in 5238 patients with type 2 diabetes who had evidence of macrovascular disease. Patients were assigned to oral pioglitazone titrated from 15...
Le role des centres de convention du diabete en Belgique. (2005)
We briefly present the modes of functioning of Diabetes Convention Centres in Belgium. In those hospital centres, patients with both type 1 or type 2 diabetes, treated by at least two insulin...
Type 2 diabetes is frequently associated with other comorbidities among which abdominal obesity, arterial hypertension, dyslipidaemia and a prothrombotic state. All these cardiovascular risk factors...
Diabete sucre iatrogene: l'exemple des anti-psychotiques atypiques. (2005)
As an example of iatrogenic diabetes, we discuss the problem of diabetes mellitus in patients receiving atypical antipsychotics. The risk of diabetes mellitus appears to be different according to...
La neuropathie autonome cardiaque diabetique. (2005)
Philips, Jean-Christophe, Marchand, Monique, Scheen, André
Cardiac autonomic neuropathy (CAN) is a common complication of diabetes mellitus, which is associated with a higher risk of morbidity and mortality. It can be detected by analyzing spontaneous...
This paper aims at comparing two meta-analyses of clinical trials having investigated the effect of the inhibition of the renin-angiotensin system either with an angiotensin converting enzyme...
L'insulinotherapie dans le diabete de type 2. (2005)
Philips, Jean-Christophe, Scheen, André
As compared to type 1 diabetes, type 2 diabetes usually requires insulin at a late stage, after secondary failure to oral antidiabetic drugs. However, it should be pointed out that insulin therapy...
Vers une tritherapie orale dans le traitement pharmacologique du diabete de type 2? (2005)
Type 2 diabetes is a complex disease combining several disturbances in various organs, especially a defect of insulin secretion by the pancreas, an increased production of glucose by the liver and a...
Wallemacq, Caroline, Van Gaal, L F, Scheen, André
Type 2 diabetes mellitus is a common chronic disease whose economic impact on both patients and society is constantly increasing. "The Cost of Diabetes in Europe--Type 2 study" is the first...
The "Treating to New Targets" (TNT) trial compared atorvastatin 80 mg (aiming at reducing LDL cholesterol < or = 75 mg/dl) and atorvastatin 10 mg (LDL < or = 100 mg/dl as target) in 10,001 patients...
De Backer, G, De Bacquer, D, Brohet, C, De Ceukelier, S, Franck, A, Krzentowsky, G, ...
These recommandations are largely based on the "European Guidelines on Cardiovascular Disease Prevention in Clinical Practice" proposed by the "Third Joint Task Force of European and other Societies...
Prevention du diabete de type 2: un nouveau defi de sante publique. (2005)
Owing to the epidemics of type 2 diabetes, it is important to develop strategies of prevention of the disease. The first step should detect patients at risk, in function of simple anamnesis, clinical...
Complications cutanees de l'insulinotherapie un probleme iatrogene sur le declin. (2005)
Pierard, Claudine, Hermanns, Trinh, Scheen, André, Pierard, Gérald
Insulin therapy is increasingly used. Hopefully, its complications are steadily decreasing in incidence since the introduction of new generations of insulin. The main cutaneous side effects were...
Obesite et diabete de type 2. (2005)
Rorive, Marcelle, Letiexhe, Michel, Scheen, André, Ziegler, O
Obesity is an epidemic disease associated with numerous cardiovascular risk factors as diabetes mellitus, dyslipidemia, hypertension. Insulin resistance seems to be an important promoter for the...
Drug interactions of clinical importance with antihyperglycaemic agents: an update. (2005)
Because management of type 2 diabetes mellitus usually involves combined pharmacological therapy to obtain adequate glucose control and treatment of concurrent pathologies (especially dyslipidaemia...
De Backer, G, De Bacquer, D, Brohet, C, De Ceukelier, S, Franck, A, Krzentowsky, G, ...
These recommendations are largely based on the Executive Summary of the "European Guidelines on Cardiovascular Disease Prevention in Clinical Practice" proposed by the "Third Joint Task Force of...
Le medicament du mois. L'insuline detemir (Levemir) (2005)
Scheen, André, Radermecker, Régis, Philips, Jean-Christophe, Paquot, Nicolas
Insulin detemir (Levemir) is a soluble long acting human insulin analogue acylated with a 14-carbon fatty acid. The fatty acid modification allows insulin detemir to reversibly bind to albumin,...
L'initiative pour la promotion de la qualite et epidemiologie du diabete sucre (IPQED). (2005)
Nobels, F, Debacker, Nathalie, Scheen, André
Since 2001, the "Diabetes Convention Centres" in Belgium participated to a survey, called IPQED ("Initiative for the Promotion of Quality and Epidemiology of Diabetes mellitus), every 12-18 months....
Diabetes mellitus in the elderly: insulin resistance and/or impaired insulin secretion? (2005)
Elderly people are more glucose intolerant and insulin resistant than young individuals, and many of them will develop type 2 diabetes. It remains, however, controversial whether this decrease in...
Triple therapie orale dans le diabete de type 2. (2005)
Type 2 diabetes has a complex pathophysiology, combining a defect of insulin secretion by the pancreas, an increased glucose production by the liver and a reduced insulin-mediated glucose uptake by...
Hemochromatose et diabete sucre: approche diagnostique et evolution clinique. (2005)
Thielen, Vinciane, Radermecker, Régis, Philips, Jean-Christophe, Paquot, Nicolas, Scheen, André
We report the characteristics of diabetes mellitus in 10 patients with a suspicion of hereditary hemochromatosis. The results of this personal series were compared to literature's data described in a...
Les insulinosensibilisateurs. (2005)
Scheen, André, Paquot, Nicolas
Insulin resistance has a genetic background and its phenotypic expression is triggered by fat diet, lack of physical activity and obesity. It provokes a stress on B cells, tends to increase blood...
L'insulinotherapie par pompe externe a perfusion continue d'insuline. (2005)
Radermecker, Régis, Hermans, M. P., Legrand, Delphine, Scheen, André
Type I diabetes mellitus requires an exogenous supply of insulin that ideally mimics physiological insulin secretion. The treatment goal is to achieve normoglycaemia in order to prevent or delay...
Van Gaal, Luc F, Rissanen, Aila M, Scheen, André, Ziegler, Olivier, Rossner, Stephan
BACKGROUND: In animal models, cannabinoid-1 receptor (CB1) blockade produces a lean phenotype, with resistance to diet-induced obesity and associated dyslipidaemia. We assessed the effect of...
La place de la transplantation pancreatique dans le traitement du diabete. (2005)
De Roover, Arnaud, Detry, Olivier, Coimbra Marques, Carla, Bonvoisin, Catherine, Beaujean, M A, Krzesinski, Jean-Marie, ...
Pancreas transplantation has now become an established option in the treatment of diabetic complications. It normalizes glucose metabolism, prevents, stabilizes and improves the evolution of...
Scheen, André, Letiexhe, Michel, Rorive, Marcelle, De Flines, Jenny, Luyckx, Françoise, Desaive, Claude
The 10-year results of the prospective, controlled Swedish Obese Subjects Study were recently reported in the New England Journal of Medicine by L. Sjostrom and colleagues. This trial compared obese...
Scheen, André, Paquot, Nicolas
PPARs ("Peroxisome Proliferator-Activated Receptors") belong to a superfamily of nuclear receptors with several isoforms, among which PPAR-alpha mainly located in the liver and PPAR-gamma mainly...
Quelles indications pour les statines hormis le traitement de l'hypercholesterolemie? (2005)
Scheen, André, Sadzot, Bernard
Statins are essential drugs for the prevention of coronary and cerebral vascular complications. Besides their specific cholesterol-lowering effect, these agents exert various pleiotropic effects,...
Le medicament du mois: Olmesartan medoxomil (Belsar ou Olmetec) (2004)
Krzesinski, Jean-Marie, Scheen, André
Olmesartan medoxomil (Belsar, Olmetec) developed by Sankyo Pharma and proposed by Sankyo Pharma but also Menarini is a new angiotensin II ATI receptor blocker. Its indication is the treatment of...
Marre, M, Puig, JG, Kokot, F, Fernandez, M, Jermendy, G, Opie, L, ...
Objectives To test whether microalbuminuria in patients with type 2 diabetes and hypertension is primarily dependent on the severity of hypertension, and to compare the effectiveness of two anti...
Oral glucose tolerance tests in schizophrenic patients treated with antipsychotics (2004)
De Hert, Marc, Van Eyck, Dominique, Hermans, Gilberte, Peuskens, Hendrik, Wampers, Martien, De Patoul, A, ...
Objective. –A recent consensus conference has proposed guidelines for the monitoring for diabetes in patients with schizophrenia and also identifies the need of long-term prospective studies....
Estimation of renal function in anorexia nervosa (2004)
Delanaye, Pierre, Radermecker, Régis, Saint-Remy, Annie, Depas, Gisèle, Chapelle, Jean-Paul, Gielen, Jacques, ...
Réunion de la Société Belge de Néphrologie
Estimation de la fonction rénale chez le patient anorexique (2004)
Delanaye, Pierre, Radermecker, Régis, Saint-Remy, Annie, Chapelle, Jean-Paul, Depas, Gisèle, Foidart, Jacqueline, ...
Congrès annuel de l’ALFEDIAM
Acanthosis nigricans associated with insulin resistance : pathophysiology and management. (2004)
Hermanns, Trinh, Scheen, André, Pierard, Gérald
The association of acanthosis nigricans, skin tags, diabetes mellitus due to insulin resistance, and obesity in adolescents and young adults represents a well defined syndrome. Hyperandrogenism may...
Scheen, André, Kulbertus, Henri
INTERHEART is a standardised case-control study of acute myocardial infarction in 52 countries representing every inhabited continent. 15152 cases and 14820 controls were enrolled. Collectively, 9...
Rofecoxib (Vioxx), the first COX-2 selective non-steroidal anti-inflammatory drug (NSAID), was recently withdrawn by Merck Sharp & Dohme. Indeed, both observational studies and randomised clinical...
Prevention of cardiovascular diseases should primarily focus on high-risk individuals. In the absence of atherosclerosis manifestations, such persons may be screened by the calculation of the...
Actualites therapeutiques 2003-2004. (2004)
The most important drugs registered and/or launched in Belgium during the last year in the various disciplines of internal medicine will be briefly described. The main characteristics of each...
Le medicament du mois. Ezetimibe (Ezetrol). (2004)
Ezetimibe (Ezetrol), recently launched in Belgium by Merck Sharp& Dohme and Schering Plough, is presented as 10 mg tablets. It belongs to a new class of lipid-lowering agents that selectively inhibit...
L'hypoglycemie reactive: un phenomene critique mysterieux, insidieux, mais non dangereux. (2004)
Scheen, André, Lefebvre, Pierre
Numerous individuals complain of malaise attributed to hypoglycaemia. However, the diagnosis of hypoglycaemia is rarely documented and most often overstated. Reactive hypoglycaemia in the...
Scheen, André, Kulbertus, Henri
Statins, as compared to placebo, have proven their efficacy in reducing cardiovascular events in patients with or without cardiovascular disease and in a large range of cholesterol levels. Two new...
Le medicament du mois. Insuline glargine (Lantus). (2004)
Insulin glargine (Lantus) is a human insulin analogue produced by recombinant DNA technology and recently launched by Aventis. Modification of the human insulin molecule at position A21 and at the...
Le medicament du mois. Rosuvastatine (Crestor). (2004)
Rosuvastatin (Crestor) has been recently launched in Belgium by AstraZeneca. This new statin is indicated for the treatment of primary hypercholesterolaemia or combined dyslipidaemia, when changes in...
Scheen, André, Radermecker, Régis, Philips, Jean-Christophe
The results of DIGAMI-2 () trial were presented at the 40th scientific congress of the European Association for the Study of Diabetes (EASD) in Munich on September 6, 2004. The main objective of this...
Scheen, André, Radermecker, Régis, Philips, Jean-Christophe
The 64th scientific congress of the American Diabetes Association had a special session devoted to the presentation of the results from three clinical trials: 1) the first multicentre international...
Le medicament du mois: Olmesartan medoxomil (Belsar ou Olmetec). (2004)
Krzesinski, Jean-Marie, Scheen, André
Olmesartan medoxomil (Belsar, Olmetec) developed by Sankyo Pharma and proposed by Sankyo Pharma but also Menarini is a new angiotensin II ATI receptor blocker. Its indication is the treatment of...
Warzee, Fabian, Legrand, Victor, Scheen, André
Coronary revascularization procedures are associated with less favourable outcomes in diabetic patients as compared to non-diabetic individuals. Especially, percutaneous coronary angioplasty (PTCA)...
Warzee, Fabian, Legrand, Victor, Scheen, André
Coronary artery revascularization procedures provide less favourable results in diabetic patients than in non-diabetic individuals. Especially, percutaneous coronary angioplasty (PTCA) is associated...
Warzee, Fabian, Legrand, Victor, Scheen, André
Diabetes mellitus, essentially type 2 diabetes, is markedly associated with a high risk of cardiovascular diseases, especially coronary artery disease (CAD). Revascularization techniques, first...
Davidson, Jaime A, Scheen, André, Howlett, Harry C S
It is important to manage blood glucose intensively in patients with type 2 diabetes mellitus in order to reduce the risk of long-term complications. Oral combination therapy that addresses insulin...
Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system. (2004)
Type 2 diabetes mellitus is becoming a major health problem associated with excess morbidity and mortality. As the prevalence of type 2 diabetes is rapidly increasing, prevention of the disease...
Management of the metabolic syndrome. (2004)
The metabolic syndrome (MetS) is strongly associated with insulin resistance and consists of a constellation of factors that raise the risk for cardiovascular diseases and diabetes mellitus....
Acanthosis nigricans associated with insulin resistance : pathophysiology and management. (2004)
Hermanns, Trinh, Scheen, André, Pierard, Gérald
The association of acanthosis nigricans, skin tags, diabetes mellitus due to insulin resistance, and obesity in adolescents and young adults represents a well defined syndrome. Hyperandrogenism may...
Pathophysiology of insulin secretion. (2004)
Defects in pancreatic islet beta-cell function play a major role in the development of diabetes mellitus. Type 1 diabetes is caused by a more or less rapid destruction of pancreatic beta cells, and...
Diabetes is still a risk factor for restenosis after drug-eluting stent in coronary arteries. (2004)
The inhibition of the renin-angiotensin system (RAS) with either angiotensin converting enzyme inhibitors (ACEIs) or AT1 angiotensin receptor blockers (ARBs) consistently and significantly reduces...
Most individuals with arterial hypertension or congestive heart failure are insulin-resistant and at a higher risk of developing type 2 diabetes (T2DM). The inhibition of the renin-angiotensin system...
Letiexhe, Michel, Desaive, Claude, Lefebvre, Pierre, Scheen, André
Most reports investigating the hormonal and metabolic effects of bariatric surgery studied obese subjects after partial weight loss only. Nevertheless, all studies showed significant improvements of...
Radermecker, Régis, Scheen, André
The hypoglycaemic coma is a severe complication for type 1 diabetic patients. Rarely fatal it may be associated with various paroxysmal accidents, potentially harmful, especially during driving....
Le medicament du mois. Valdecoxib (Bextra). (2004)
Scheen, André, Malaise, Michel
Valdecoxib (Bextra tablets of 10 mg and 20 mg) is a new non steroidal antiinflammatory drug (NSAID) that selectively inhibits COX-2 isoform of cyclo-oxygenase. It is indicated for the symptomatic...
Hemochromatose et diabete. (2004)
Thielen, Vinciane, Paquot, Nicolas, Scheen, André
Nowadays, haemochromatosis is often diagnosed when the patient is monosymptomatic. Diabetes is frequently the first expression of the disease. So, it is important to know the clinical and biologic...
Radermecker, Régis, Scheen, André
Portable insulin infusion devices are effective and safe insulin delivery systems for managing diabetes mellitus, especially type 1 diabetes. Rapidly absorbed insulin analogues, such as insulin...
Gaspard, Ulysse, Scheen, André, Endrikat, J, Buicu, C, Lefèbvre, Pierre, Gerlinger, C, ...
In this open-label, randomized study we compared the influence of a new oral contraceptive containing 30 microg ethinylestradiol and 3 mg drospirenone (Yasmin) with a reference preparation containing...
Mogensen, Carl Erik, Viberti, Giancarlo, Halimi, Serge, Ritz, Eberhard, Ruilope, Luis, Jermendy, György, ...
Microalbuminuria in diabetes is a risk factor for early death and an indicator for aggressive blood pressure (BP) lowering. We compared a combination of 2 mg perindopril/0.625 mg indapamide with...
Radermecker, Régis, Magis, Delphine, Selam, JL, Scheen, André
The improvement of diabetic patients' glycaemic status requires an increase of fingerstick blood glucose measurements. Among the possibilities available to assess diabetes' control, we will consider...
Martalo, O, Pierard-Franchimont, Claudine, Scheen, André, Pierard, Gérald
Obesity is a chronic multifactorial disease representing a major health problem. Among its consequences, diverse facets of the cutaneous physiology are altered. Some dermatoses are also more...
Alcool, sensibilite a l'insuline et diabete sucre. (2003)
Magis, Delphine, Jandrain, Bernard, Scheen, André
The relationship between alcohol consumption and insulin resistance shows a U-shaped curve: insulin resistance is minimal in individuals with regular mild to moderate alcohol consumption and...
Le medicament du mois. Gliclazide a liberation modifiee (Uni Diamicron). (2003)
Gliclazide modified release that has been recently launched by Servier (Uni Diamicron 30 mg) is a new formulation of gliclazide to be given once daily. The original hydrophilic matrix improves the...
The Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA), performed in hypertensive patients with coronary risk and the Collaborative AtoRvastatin Diabetes Study (CARDS),...
Le medicament du mois. Le vardenafil (Levitra). (2003)
Vardenafil (Levitra), recently launched in Belgium by Bayer and Glaxo-SmithKline, is a new drug that potently and selectively inhibits phosphodiesterase type 5 (PDE5) in the cavernosum tissue of the...
Glucovance, recently launched by Merck-Lipha (Glucovance 500 mg/2.5 mg and Glucovance 500 mg/5 mg), is a fixed combined therapy of a sulphonylurea (glibenclamide 2.5 or 5 mg) and a biguanide...
Luyckx, Françoise, Scheen, André
The oral glucose tolerance test (OGTT) has been widely used for the diagnosis of diabetes mellitus, gestational diabetes or impaired glucose tolerance. However, since 1997, OGTT is not considered...
Le syndrome metabolique: definitions et donnees epidemiologiques. (2003)
Scheen, André, Luyckx, Françoise
The metabolic syndrome is strongly related to visceral obesity and associated with a high risk of cardiovascular morbidity and mortality. Since the original description of Reaven in 1988, several...
Scheen, André, Lefebvre, Pierre, Kulbertus, Henri
In the June 28, 2003 issue of the British Medical Journal, an extensive literature survey based on various large meta-analyses of the efficacy and safety of the reduction of four cardiovascular risk...
Alcool, sensibilite a l'insuline et diabete sucre. (2003)
Magis, Delphine, Jandrain, Bernard, Scheen, André
The relationship between alcohol consumption and insulin resistance shows a U-shaped curve: insulin resistance is minimal in individuals with regular mild to moderate alcohol consumption and...
Strategies de prevention du diabete de type 1: le point en 2003. (2003)
Philips, Jean-Christophe, Scheen, André
Type 1 diabetes is caused by a progressive autoimmune destruction of insulin-producing B cells of the pancreatic islets of Langerhans. The autoimmune process begins years before the B-cell...
Prevention cardio-vasculaire par les statines: faut-il encore doser le cholesterol? (2003)
Scheen, André, Kulbertus, Henri
Statins, the most popular lipid-lowering agents, have proven their efficacy in preventing cardiovascular events in subjects with lower and lower initial plasma cholesterol levels. Besides, the...
Scheen, André, Legrand, Victor
The multicentre placebo-controlled double-blind "EUropean trial on Reduction Of cardiac events with Perindopril in patients with stable coronary Artery disease" (EUROPA) assessed whether the...
Cardiovascular morbidity is a major burden in patients with type 2 diabetes. The Steno-2 Study compared the effect of a targeted, intensified, multifactorial intervention (n = 80) with that of a...
Comment j'explore ... les secrets d'une meta-analyse. (2003)
Meta-analysis is becoming a key partner of Evidence-Based Medicine. This statistical tool is currently used in most systematic reviews and allows to quantitatively synthesize the results of several...
L'etude clinique du mois. L'etude ALLHAT-LLT. (2003)
Kulbertus, Henri, Scheen, André
ALLHAT-LLT was part of the ALLHAT study. The purpose was to determine whether pravastatin compared with usual care reduces all-cause mortality in older, moderately hypercholesterolaemic, hypertensive...
Scheen, André, Krzesinski, Jean-Marie
Antihypertensive therapy is well established to reduce hypertension-related morbidity and mortality, but the optimal first-step therapy is still controversial. The "Antihypertensive and...
Scheen, André, Bruwier, Geneviève, Schmitt, H
This paper reports the results of the "DREAM" ("Diabetes REinforcement of Adequate Management") study performed among 42 general practitioners. A treatment algorithm was proposed to intensify the...
Martalo, Oriane, Pierard, Claudine, Scheen, André, Pierard, Gérald
Obesity is a chronic multifactorial disease representing a major health problem. Among its consequences, diverse facets of the cutaneous physiology are altered. Some dermatoses are also more...
Weekers, Laurent, Scheen, André, Rorive, Georges
Diabetic nephropathy is one of the leading causes of end-stage renal failure in western countries. This disease develops over several years. Early stages, if they are detected in time, can lead to...
Pathophysiology of type 2 diabetes. (2003)
Type 2 diabetes mellitus is a heterogeneous syndrome characterized by abnormalities in carbohydrate and fat metabolism. The causes of type 2 diabetes are multi-factorial and include both genetic and...
Treatment of type 2 diabetes. (2003)
Type 2 diabetes is a heterogeneous disease resulting from a dynamic interaction between defects in insulin secretion and insulin action. As most subjects are overweighted or obese, the initial...
Scheen, André, Luyckx, Françoise
Nonalcoholic steatohepatitis (NASH), along with other forms of nonalcoholic fatty liver disease, is an increasingly common clinico-pathological syndrome. It is frequently associated with obesity,...
Current management strategies for coexisting diabetes mellitus and obesity. (2003)
Besides genetic predisposition, obesity is the most important risk factor for the development of diabetes mellitus. Weight reduction has been shown to markedly improve blood glucose control and...
Type 2 diabetes mellitus is a major health problem associated with excess morbidity and mortality. As the prevalence of this metabolic disorder is rapidly increasing and current treatment fails to...
L'adiponectine: une nouvelle adipocytokine. (2003)
Lebas, Eglantine, Paquot, Nicolas, Scheen, André
Adipose tissue is not simply a store of excess energy, but also secretes a variety of proteins into circulating blood that influence systemic metabolism. These include tumor necrosis factor...
Prevention des hypoglycemies chez le patient diabetique de type 1. (2003)
Radermecker, Régis, Jandrain, Bernard, Paquot, Nicolas, Philips, Jean-Christophe, Contessi, Elide, Lavigne, Myriam, ...
Hypoglycaemia is the most common metabolic disorder in type 1 diabetic patients. It is rarely dangerous, but significantly alters the quality of life and hinders the achievement of "normoglycaemia"....
Prevention cardio-vasculaire chez le patient diabetique de type 2. (2003)
Paquot, Nicolas, Scheen, André
It is estimated that 80% of individuals with type 2 diabetes die of cardiovascular diseases. Several factors account for the accelerated atherosclerosis present in diabetic patients. These include...
Scheen, André, Paquot, Nicolas
Even if type 2 diabetes is a complex disease combining hyperglycaemia and various other metabolic abnormalities. Reduction of chronic hyperglycemia, assessed by glycated haemoglobin (HbA1c), allows...
Prevention du diabete de type 2: style de vie ou medicaments? (2003)
Scheen, André, Letiexhe, Michel, Ernest, Philippe
The World Health Organisation strongly recommends strategies for the prevention of type 2 diabetes, knowing the epidemics of the disease and its strong association with that of obesity. Several...
Radermecker, Régis, Magis, Delphine, Selam, J L, Scheen, André
The improvement of diabetic patients' glycaemic status requires an increase of fingerstick blood glucose measurements. Among the possibilities available to assess diabetes' control, we will consider...
Comment je traite ... une hypoglycemie grave chez un patient diabetique. (2003)
Radermecker, Régis, Philips, Jean-Christophe, Scheen, André
Severe hypoglycaemic episodes are defined as need of assistance and may progress to profound coma. They can occur in patients treated with insulin, generally for type 1 diabetes, or in patients...
Philips, Jean-Christophe, Radermecker, Régis, Scheen, André
Diabetes mellitus places an enormous burden on patients, their relatives and the society. Current therapies do not provide sufficiently tight control of blood glucose to avoid diabetic complications....
Mogensen, Carl Erik, Viberti, Giancarlo, Halimi, Serge, Ritz, Eberhard, Ruilope, Luis, Jermendy, Gyorgy, ...
Microalbuminuria in diabetes is a risk factor for early death and an indicator for aggressive blood pressure (BP) lowering. We compared a combination of 2 mg perindopril/0.625 mg indapamide with...
Gaspard, Ulysse, Scheen, André, Endrikat, J, Buicu, C, Lefebvre, Pierre, Gerlinger, C, ...
In this open-label, randomized study we compared the influence of a new oral contraceptive containing 30 microg ethinylestradiol and 3 mg drospirenone (Yasmin) with a reference preparation containing...
Lüdicke, Frank, Gaspard, Ulysse J., Demeyer, Fabienne, Scheen, André, Lefèbvre, Pierre
This study compared the impact on carbohydrate metabolism of two combinedoral contraceptives (COCs). This open-label, single-center trial enrolled participants for a total of 15 cycles. Thirty-six...
Weets, Ilse, Siraux, Valérie, Daubresse, Jean-Claude, De Leeuw, Ivo H., Féry, Françoise, Keymeulen, Bart, ...
We investigated inaugural disease phenotype in relation to the presence or absence of diabetes-associated autoantibodies and human leukocyte antigen (HLA) DQ risk genotypes in adult-onset diabetic...
Siraux, Valerie, Daubresse, Jean-Claude, De Leeuw, Ivo H, Féry, Francoise, Keymeulen, Bart, ...
We investigated inaugural disease phenotype in relation to the presence or absence of diabetes-associated autoantibodies and human leukocyte antigen (HLA) DQ risk genotypes in adult-onset diabetic...
La cardiologie preventive: strategies chez l'enfant (2002)
Massin, M, Vandoorne, Chantal, Coremans, C, Lepage, P, Scheen, André
The importance of preventive cardiology in youth has been established by several critical observations: there is evidence that the atherogenic process begins in childhood, and that the degree of...
Actualites therapeutiques 2002 (1). (2002)
The most important drugs registered and/or launched in Belgium during the last year in the various disciplines of internal medicine will be briefly described. The main characteristics of each...
Philips, Jean-Christophe, Scheen, André
ENDIT ("European Nicotinamide Diabetes Intervention Trial") is a large placebo-controlled randomised clinical trial that aimed at studying the efficacy of nicotinamide in the prevention of type 1...
The results of the XENDOS study were presented by Professor Lars Sjostrom (Gothenburg, Sweden), on August 26, 2002, at the 9th International Congress on Obesity in Sao Paulo, Brazil. XENDOS (XENical...
The prospective placebo-controlled LIPS study ("Lescol Intervention Prevention Study") demonstrated a significant cardiovascular protection by fluvastatin in patients with coronary artery disease...
Type 2 diabetes mellitus and arterial hypertension are part of the insulin resistance syndrome. Besides a metabolic component, insulin resistance has also an haemodynamic component, especially in...
Philips, Jean-Christophe, Scheen, André
Type 1 diabetes is an autoimmune disease leading to a progressive exhaustion of the insulin secretion and a destruction of the B-cells. Attempts of preservation of insulin-producing B-cells can be...
Pieges et conseils a propos de l'utilisation des antidiabetiques oraux conventionnels. (2002)
The main pitfalls regarding the use of sulphonylureas and metformin in type 2 diabetic patients are described and illustrated by a clinical case. Advices are given in order to avoid the occurrence of...
Un diabete peut en cacher un autre. (2002)
The abrupt interruption of insulin therapy in a severely obese diabetic woman submitted to a protein-sparing modified fast in a metabolic ward led to a severe ketoacidosis. This complication occurred...
The LIFE study ("Losartan Intervention For Endpoint reduction in hypertension study") demonstrated a significant cardiovascular protection by an angiotensin AT1 receptor antagonist, losartan, in...
Le medicament du mois. La rosiglitazone (Avandia). (2002)
Rosiglitazone (Avandia, Glaxo-SmithKline) belongs to a new family of oral hypoglycaemic agents, thiazolidinediones or glitazones. These molecules act as selective agonists of nuclear receptors (PPAR...
Kulbertus, Henri, Scheen, André
Statins reduce coronary and cerebrovascular mortality and morbidity in middle-aged individuals. Until recently, their efficacy and safety in elderly people had not yet been firmly established....
L'etude clinique du mois. La MRC/BHF Heart Protection Study. (2002)
Kulbertus, Henri, Scheen, André
20,536 adults (15,454 men and 5,082 women, aged 40-80 years) with coronary heart disease, other occlusive arterial disease or diabetes mellitus were randomly allocated to receive 40 mg simvastatin...
La cardiologie preventive: strategies chez l'enfant. (2002)
Massin, M, Vandoorne, Chantal, Coremans, C, Lepage, Ph, Scheen, André
The importance of preventive cardiology in youth has been established by several critical observations: there is evidence that the atherogenic process begins in childhood, and that the degree of...
Tabagisme, insulinoresistance et diabete de type 2. (2002)
Magis, Delphine, Geronooz, I, Scheen, André
Smoking is a major risk factor for cardiovascular disease. It is associated with endothelial dysfunction and lipid disorders similar to those found in the insulin resistance syndrome. Studies have...
Obesity and liver disease. (2002)
Scheen, André, Luyckx, Françoise
Non-alcoholic steatohepatitis (NASH) is a disease of emerging identity and importance. It is frequently associated with obesity, especially visceral fat, and is intimately related to fatty liver and...
Weets, Ilse, Siraux, Valerie, Daubresse, Jean-Claude, De Leeuw, Ivo H, Fery, Francoise, Keymeulen, Bart, ...
We investigated inaugural disease phenotype in relation to the presence or absence of diabetes-associated autoantibodies and human leukocyte antigen (HLA) DQ risk genotypes in adult-onset diabetic...
Hepatic insulin resistance in obese non-diabetic subjects and in type 2 diabetic patients. (2002)
Paquot, Nicolas, Scheen, André, Dirlewanger, Mirjam, Lefebvre, Pierre, Tappy, Luc
OBJECTIVE: Obese non-diabetic patients are characterized by an extra-hepatic insulin resistance. Whether obese patients also have decreased hepatic insulin sensitivity remains controversial. RESEARCH...
Are all glitazones the same? (2002)
This supplement focuses on the benefits of targeting insulin resistance through therapy with a new class of oral antidiabetic agents, the thiazolidinediones (TZDs) or 'glitazones'. There are...
L'hyperglycemie post-prandiale. II. Approches therapeutiques medicamenteuses. (2002)
Scheen, André, Letiexhe, Michel, Geronooz, I, Paquot, Nicolas, Jandrain, Bernard
Besides dietary approaches, various pharmacological means have been recently developed in order to better control postprandial hyperglycaemia. This objective may be obtained: 1) by slowing down the...
Scheen, André, Paquot, Nicolas, Jandrain, Bernard, Lefebvre, Pierre
Postprandial hyperglycaemia depends on the amount and type of ingested carbohydrates and/or the degree of inhibition of hepatic glucose output following a meal. The kinetics of carbohydrate...
Comment j'explore ... Le risque d'un patient d'evoluer vers un diabete de type 2. (2002)
Scheen, André, Paquot, Nicolas, Jandrain, Bernard
Both the prevalence and the incidence of type 2 diabetes are increasing rapidly. Effective prevention measures, including lifestyle or drug prescription, have been recently reported. It is thus...
Scheen, André, Ernest, Philippe
Besides genetic predisposition, obesity is the most important risk factor for the development of type 2 diabetes mellitus. Even modest weight reduction can improve blood glucose control in overweight...
Results of obesity treatment. (2002)
Obesity is a chronic disease so that results of obesity treatment should only be evaluated on a long-term basis. The present paper aims at analyzing the long-term (1 year or more) results of three...
Ludicke, Frank, Gaspard, Ulysse, Demeyer, Fabienne, Scheen, André, Lefebvre, Pierre
This study compared the impact on carbohydrate metabolism of two combinedoral contraceptives (COCs). This open-label, single-center trial enrolled participants for a total of 15 cycles. Thirty-six...
Age- and Body Mass Index-Related Changes in Cutaneous Shear Wave Velocity (2001)
Hermanns-Le, T, Jonlet, F, Scheen, André, Pierard, Gérald
BACKGROUND: The in vivo visco-elastic characteristics of skin depend on a series of physiopathological parameters. Among them, the age-related intrinsic tensile properties and the preconditioning of...
Obesite: aspects therapeutiques (2001)
Obesity is now recognized as a chronic disease. Its treatment implies a prolonged negative energy balance, by reducing caloric intake and/or increasing energy expenditure. In practice, three...
Amputations in Diabetic Patients: A Plea for Footsparing Surgery (2001)
Van Damme, Hendrik, Rorive, Marcelle, Martens De Noorthout, B M, Quaniers, Janine, Scheen, André, Limet, Raymond
The authors observed a rather high rate of primary major amputation (above-knee or below-knee) performed for diabetic foot problems as well as an important revision rate for minor amputations...
A large Belgian, prospective, controlled study was performed in 1.548 critically ill patients (83% without history of diabetes) hospitalised in a surgical intensive care unit. On admission, patients...
De Flines, Jenny, Letiexhe, Michel, Desaive, Claude, Scheen, André
Morbid obesity is a crucial risk factor in the development of type 2 diabetes and is often associated with a metabolic syndrome closely linked to insulin resistance. This case report illustrates the...
Info-congres. La cochrane collaboration, porte-parole de la medecine factuelle. (2001)
During the 9th International Cochrane Colloquium (Lyon October 9-13, 2001), around 700 participants discussed about how to make the evidence dissemination process more efficient in order to promote...
PROGRESS ("Perindopril pROtection aGainst REcurrent Stroke Study") demonstrated that blood-pressure lowering treatment with perindopril, an angiotensin converting enzyme inhibitor (combined with the...
Pharma clinics le medicament du mois. Le nebivolol (Nobiten). (2001)
Nebivolol (Nobiten, Menarini) is a new beta-blocker recommended for the management of essential hypertension, at a dose of 5 mg once daily. It is administered as a racemic mixture of equal...
We report the positive results of two large prospective studies of pharmacological prevention of type 2 diabetes presented at the EASD Congress in Glasgow, September 12, 2001. In the "Diabetes...
Obesite: aspects therapeutiques. (2001)
Obesity is now recognized as a chronic disease. Its treatment implies a prolonged negative energy balance, by reducing caloric intake and/or increasing energy expenditure. In practice, three...
Muls, E, Kolanowski, J, Scheen, André, Van Gaal, L
OBJECTIVE: Assessment of the effects of orlistat 120 mg three times daily vs placebo on weight loss and serum lipids in obese hypercholesterolemic patients. DESIGN: A 24 week multicentre,...
Hepatotoxicity with thiazolidinediones: is it a class effect? (2001)
Decreased insulin sensitivity plays a major role in various human diseases. particularly type 2 diabetes mellitus, and is associated with a higher risk of atherosclerosis and cardiovascular...
Pharma-clinics. Le medicament du mois. La sibutramine (Reductil). (2001)
Sibutramine (Reductil, Abbott-Knoll, 10 mg and 15 mg) is a new appetite regulator recommended in the treatment of obesity. It is a noradrenaline and 5-hydroxytryptamine reuptake inhibitor which...
Scheen, André, Philips, Jean-Christophe, Luyckx, Françoise, Paquot, Nicolas, Jandrain, Bernard
Owing to the increasing prevalence of diabetes mellitus and the various aspects of this disease, we present a practical approach which allows the clinician to more easily differentiate type 1...
Actualites therapeutiques 2001. (2001)
The most important drugs registered and/or launched in Belgium during the last year in the various disciplines of internal medicine will be briefly described. The main characteristics of each...
Rhabdomyolyse fatale sous cerivastatine. (2001)
Cerivastatin was recently withdrawn from the market after the report of more than 30 deaths in the United-States among patients receiving a combination of cerivastatin and gemfibrozil, a fibrate...
Scheen, André, Geronooz, I, Marchand, Monique
Finapres is a device able to continuously and non invasively measure arterial blood pressure by photoplethysmography in the finger. It can be used in various dynamic tests which involve...
Scheen, André, Philips, Jean-Christophe
The results of the American multicentre "Diabetes Prevention Trial-Type 1" were presented by J. Skyler during the last congress of the American Diabetes Association in Philadelphia on June 23, 2001....
Scheen, André, Rorive, Marcelle, Letiexhe, Michel, Devoitille, Laurent, Jandrain, Bernard
Obesity is a mulfactorial disease whose prevalence is progressively increasing. Ideally, it requires a multidisciplinary management by medical doctors, dieticians, psychologists and kinetherapists....
The "Finnish Diabetes Prevention Study" is a prospective controlled study recently published in the New England Journal of Medicine which compared the risk of developing type 2 diabetes among 265...
Pharma-clinics. Le medicament du mois. Le repaglinide (NovoNorm). (2001)
Repaglinide (NovoNorm) is an antidiabetic oral agent of the new glinide class with insulinotropic activity. Its action on insulin secretion is more rapid and shorter than that of sulphonylurea...
Vademecum pour la bonne pratique d'une activite physique. (2001)
Scheen, André, Crielaard, Jean-Michel
The present closing article summarizes some guidelines for the good practice of physical activities in order to develop and maintain cardiorespiratory and muscular fitness, and flexibility. Advice is...
Pratique de l'exercice musculaire chez le patient diabetique. (2001)
Jandrain, Bernard, Scheen, André
Muscular exercise is recommended in patients with type 1 or type 2 diabetes mellitus and is part of the overall management, in combination with diet, oral antidiabetic agents and/or insulin. From a...
Obesity: causes and new treatments. (2001)
Lefebvre, Pierre, Scheen, André
The prevalence of obesity increases rapidly in developed and developing countries. Obesity results from a cumulative positive energy balance and is favoured by both genetic and environmental factors....
Le concept d'insulinosensibilite (2001)
Insulin resistance was already suspected in the thirties from clinical observations in diabetic patients, then better appreciated in the early sixties with the development of insulin...
Thiazolidinediones and liver toxicity. (2001)
Thiazolidinediones or glitazones specifically target insulin resistance. They have proven efficacy for reducing plasma glucose levels of type 2 diabetic patients treated with diet alone,...
Scheen, André, Rorive, Marcelle, Letiexhe, Michel
Obesity is a multifactorial disease making difficult the determination of the precise role of one specific factor such as physical activity or sedentary. Nevertheless, numerous arguments, derived...
Effets benefiques de l'activite physique sur les facteurs de risque cardio-vasculaire. (2001)
Scheen, André, Paquot, Nicolas
Numerous observational (epidemiological surveys) or interventional (controlled trials) studies demonstrated that regular physical activity increases insulin sensitivity in normal subjects and...
Adaptations hormono-metaboliques a l'exercice musculaire. (2001)
Scheen, André, Jandrain, Bernard
Physical exercise induces numerous metabolic and hormonal changes that may be influenced by various factors, among which the intensity and the duration of the exertion seem to play a major role...
Pharma clinics. Le medicament du mois. Le clopidogrel (Plavix). (2001)
Clopidogrel is launched in Belgium by Sanofi-Synthelabo and Bristol-Myers Squibb under the trade name of Plavix. It is a potent and irreversible ADP receptor antagonist that proved to be more...
Philips, Jean-Christophe, Weekers, Laurent, Scheen, André
The main objective of the CALM (Candesartan And Lisinopril Microalbuminuria) study is to assess the effect of a dual blockade of the renin-angiotensin system--using both an angiotensin converting...
The results of the "Sibutramine Trial of Obesity Reduction and Maintenance" (STORM) published in the last issue of December 2000 of the Lancet are summarized. This clinical trial (open label for the...
Pharma-clinics. Le medicament du mois. Le celecoxib (Celebrex). (2001)
Celecoxib (Celebrex, Pharmacia) is a potent and selective inhibitor of the COX-2 isoform of cyclooxygenase which is used as nonsteroidal anti-inflammatory drug (NSAID). Its current indications are...
Aggrenox, launched in Belgium by Boehringer Ingelheim, is a fixed-dose combination of extended-release dipyridamole (200 mg) and aspirin (25 mg), two antiplatelet agents with different and...
The results of the "MIRACL" trial ("Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering") were presented at the recent annual meeting of the American Heart Association in New Orleans...
Pharma-clinics. Le medicament du mois. La levofloxacine (Tavanic). (2000)
Levofloxacin, the (-)-(S)-enantiomer isolated from the racemate ofloxacin, is launched by Aventis under the trade name of Tavanic. This new oral and parenteral antibiotic belongs to the...
Based upon the positive results of a large epidemiological study and the negative results of an interventional clinical trial recently published in the New England Journal of Medicine, we will...
Luyckx, Françoise, Scheen, André
Oral glucose tolerance test (OGTT) has been widely used for the diagnosis of diabetes mellitus, gestational diabetes, impaired glucose tolerance or reactive hypoglycaemia. Simultaneous measurements...
Actualites therapeutiques 2000. (2000)
The most important drugs registered and/or launched in Belgium during the last year in the various disciplines of internal medicine will be briefly described. The originality of each molecule as well...
Clinical pharmacology and therapeutics are two complementary disciplines which should lead the medical student, through an optimized training, to a rational prescription of drugs, ultimate and...
Paquot, Nicolas, Schneiter, P, Scheen, André, Lefebvre, Pierre, Tappy, L
BACKGROUND: Obese patients are frequently characterized by insulin resistance and decreased insulin-mediated glycogen synthesis in skeletal muscle. Whether they also have impaired postprandial...
A Canadian research team recently reported a series of 7 consecutive patients with type 1 brittle diabetes who could achieve sustained excellent metabolic control in the absence of insulin therapy...
Quoi de neuf dans le domaine de l'obesite? (2000)
We will briefly comment on some interesting topics presented at the 10th European Congress on Obesity (ECO, Antwerp, Belgium, 24-27 May 2000). Special attention has been focused upon: 1) the...
Pharma-clinics. Le medicament du mois. Le rofecoxib (Vioxx). (2000)
Rofecoxib (Vioxx, Merck Sharp & Dohme) is a potent and selective inhibitor of the COX-2 isoform of cyclooxygenase which is used as a nonsteroidal anti-inflammatory drug (NSAID). It is indicated in...
Scheen, André, Rorive, Marcelle, Estrella, F, Weekers, Laurent, Lefebvre, Pierre
Diabetes mellitus is frequently associated with arterial hypertension and the combination of the two entities markedly increases the cardiovascular risk and accelerates the progression of...
Paquot, Nicolas, Scheen, André, Lefebvre, Pierre
Diabetes mellitus is a chronic disorder characterized by microvascular and cardiovascular complications that substantially increase the morbidity and mortality associated with the disease. Several...
Recommandations pour le traitement de l'obesite. (2000)
Luyckx, Françoise, Scheen, André
Obesity represents a major medical problem which is now considered more seriously from a scientific, clinical and economical point of view. Such an evolution was mandatory when considering the usual...
The present paper summarizes the last recommendations of the Belgian Lipid Club for the diagnosis and treatment of hyperlipidaemias which were published in 1999. These guidelines are in agreement...
International guidelines from the Task Force of European and other Societies on Coronary Prevention and national guidelines from the Belgian Lipid Club recently emphasized the potential interest of...
Evidence-based medicine. Apport des essais cliniques controles. (2000)
Controlled clinical trials are the support of Evidence-Based Medicine. In most instances, only them can indeed provide the demonstration of both the efficacy and safety of a pharmacological...
La mesure de l'efficacite therapeutique, etape essentielle dans la medecine factuelle. (2000)
Evidence-based medicine relies on the results from clinical trials. We will describe the various modes of expression of the results (absolute risk reduction, relative risk reduction, odds ratios,...
L'etude clinique du mois. L'apres DCCT, l'etude EDIC. (2000)
The "Diabetes Control and Complications Trial" (DCCT) demonstrated that intensive insulin therapy, by reducing HbA1c levels by about 2%, delays the onset and slows the progression of microangiopathic...
Pharma-clinics. Le medicament du mois. Le glimepiride (Amarylle). (2000)
Glimepiride, commercialized in Belgium under the trade name of Amarylle by Aventis, is a new sulphonylurea compound which is indicated in the treatment of type 2 diabetes, after diet and exercise...
Luyckx, Françoise, Delcourt, Sandrine, Philips, Jean-Christophe, Scheen, André
Diabetes mellitus is a frequent metabolic disease characterised by a complex and inconstant phenotypic expression that complicates the classification of patients and sometimes delays their optimal...
Luyckx, Françoise, Lefebvre, Pierre, Scheen, André
Non-alcoholic steatohepatitis (NASH) is a disease of emerging identity and importance, and is now considered as one of the commonest liver diseases in western countries. It is frequently associated...
L'etude clinique du mois. L'etude STOP-2 dans l'hypertension arterielle du sujet age. (2000)
After the demonstration of the efficacy of beta-blockers or diuretics versus placebo to prevent cardiovascular complications in elderly hypertensive patients in the first STOP-Hypertension study in...
Pharma-clinics. Le medicament du mois. La moxonidine (Moxon). (2000)
Moxonidine (Moxon, Solvay Pharma) is the first member of a new class of centrally-acting antihypertensive agents. The selective activation of central I1 imidazoline receptors results in an inhibition...
La grippe: de la prevention vaccinale au traitement antiviral. (2000)
Influenza is a highly infectious disease responsible for dangerous epidemics, especially in patients at high risk. The vaccine exerts a valuable protective effect estimated up to 70% and is still...
The hypothesis of the atherogenic role of oxidized. LDL lipoproteins and the observation of the longevity of individuals on a "mediterranean diet" led to the concept that antioxidant vitamins may...
From obesity to diabetes: why, when and who? (2000)
Obesity is considered as the most important risk factor for type 2 diabetes. We will briefly discuss why does obesity predispose to diabetes, when does diabetes occur in obese subjects and who among...
L'etude clinique du mois. L'etude HOPE, un essai clinique bicephale aux resultats contrastes. (2000)
The results of the HOPE ("Heart Outcomes Prevention Evaluation") study, recently published in the New England Journal of Medicine, demonstrated a highly significant cardiovascular protection by an...
Pharma clinics. Le medicament du mois. La cerivastatine (Lipobay, Cholstat). (2000)
Cerivastatin, commercialized under the trade names of Lipobay by Bayer and Cholstat by Fournier Pharma, is a new synthetic statin. Because of its high affinity for HMG-CoA reductase enzyme that it...
Various epidemiological studies suggested that individuals with high intake of antioxidant vitamins (E, A and C) have a better cardiovascular prognosis than subjects with relative deficiencies in...
Treatment of diabetes in patients with severe obesity. (2000)
Besides genetic predisposition, obesity is the most important risk factor for the development of diabetes mellitus, and weight reduction has been shown to markedly improve blood glucose control in...
Antiobesity pharmacotherapy in the management of type 2 diabetes. (2000)
Scheen, André, Lefebvre, Pierre
Obesity is a well-known risk factor for the development of Type 2 diabetes mellitus. The management of the obese diabetic patient remains a challenge for the clinician but, in any case, weight...
Paquot, Nicolas, Castillo, M J, Lefebvre, Pierre, Scheen, André
Inhibition of tumor necrosis factor (TNF)-alpha results in a marked increase in insulin sensitivity in obese rodents. We investigated the influence of a TNF antagonist [Ro 45-2081, a recombinant...
Le diabete gestationnel: definition, depistage et traitement (1999)
Geronooz, I, Scheen, André, Foidart, Jean-Michel
Defined as glucose intolerance with onset or first recognition during pregnancy, gestational diabetes mellitus represents in fact an heterogeneous clinical entity which may concern 1 to 4% of all...
Gaspard, Ulysse, Wery, Olivier, Scheen, André, Jaminet, C, Lefebvre, Pierre
OBJECTIVE: To determine in postmenopausal women the long-term effects on carbohydrate metabolism of the administration of oral micronized 17 beta-estradiol (2 mg/day continuously) and cyclical...
Scheen, André, Lefebvre, Pierre
At a time when scientists support Evidence-Based Medicine, the Parliament of Belgium has recently decided to recognize four alternative medicines, among which homeopathy. Whereas this discipline does...
The prevention of cardiovascular diseases relies upon the correction of risk factors and, more particularly, the optimal management of various metabolic abnormalities such as obesity, dyslipidaemias,...
According to a recent experimental study published in the Lancet, sleep debt, frequently imposed by the life habits of industrialized countries, results in profound metabolic (impaired glucose...
Comment j'explore ... le controle glycemique des patients diabetiques a domicile. (1999)
Self blood glucose monitoring is now a key element in the management of diabetic patients. However, in order to improve overall blood glucose control, self-monitoring should lead to self-management....
L'observance therapeutique. (1999)
Compliance is defined as the extent to which a patient's behaviour coincides with medical or health advice. Medication compliance seems to be rather low as 30 to 60% of no or poor adherence to...
Interets et limites de la diete proteique chez le patient obese diabetique de type 2. (1999)
Weight excess plays a major role in the pathophysiology of type 2 diabetes but only a minority of patients succeed in following a restrictive calorie diet in the long-term, able to reduce body weight...
The results of the HOPE ("Heart Outcomes Prevention Evaluation") study were presented at the XXIst Congress of the European Society of Cardiology in Barcelona (August 28-September 1, 1999). In...
Hypertension arterielle et diabete de type 2. (1999)
Scheen, André, Estrella, F, Weekers, Laurent
Diabetes mellitus is frequently associated with arterial hypertension and the combination of both entities markedly increases the vascular risk. In type 2 diabetes, hypertension appears very early,...
The "Veterans Affairs Cooperative Studies Program High-Density Lipoprotein Cholesterol Intervention Trial" (VA-HIT) is a large randomised, double-blind, placebo-controlled clinical trial for the...
Dysthyroidies et dyslipidemies. (1999)
Deschampheleire, M, Luyckx, Françoise, Scheen, André
While overt thyroid disturbances, characterized by symptoms and/or clinical signs with abnormal serum levels of thyroid hormones, are generally associated with perturbations in the lipid profile, the...
Actualites therapeutiques 1999. (1999)
The most important drugs registered and/or launched in Belgium during the last year in the various disciplines of internal medicine will be briefly described. The originality of each molecule as well...
Orlistat (Xenical), whose original mechanism of action consists of the selective inhibition of gastrointestinal lipases, has been recently commercialized for the treatment of obesity. Despite its...
Scheen, André, Paquot, Nicolas
Type 2 diabetes is a prevalent disease, with high morbidity and mortality rates, which is usually managed by general practitioners. We will discuss the new diagnostic approaches, the glycaemic goals...
Comment apprecier chez l'homme l'action de l'insuline en recherche et en pratique. (1999)
Various methods have been proposed to assess insulin action in vivo, from the most complex to the simplest. All methods are based on the comparison of plasma concentrations of glucose and insulin,...
Traitement de l'hyperlipidemie combinee: fibrate ou/et statine? (1999)
Combined hyperlipidaemia, associating hypercholesterolaemia and hypertriglyceridaemia, is a common metabolic disorder with a prevalence of about 1/500. It has a genetic background, but its phenotype...
Scheen, André, Lefebvre, Pierre
Insulin resistance is a major component of type 2 diabetes; therefore, an insulin sensitizer agent like the thiazolidinedione compound troglitazone is considered a very promising drug. Troglitazone...
A recent analysis of the literature, published in the 19 May issue of the JAMA, once again demonstrates the efficacy of warfarin, and its superiority on aspirin, in preventing stroke in patients with...
Comment j'explore ... un sujet avec un exces ponderal ou une obesite. (1999)
Scheen, André, Luyckx, Françoise
The evaluation of an obese subject aims at better understanding the disease, its causes and consequences, in order to optimize its management. Schematically, this task can be done in three successive...
Scheen, André, Paquot, Nicolas, Lefebvre, Pierre
Type 2 diabetes mellitus is a dynamic disease whose natural history is characterized by a progressive aggravation leading to a progressively severe hyperglycaemia, which generally requires a more...
Diabete gestationnel: signification pronostique pour l'enfant. (1999)
Geronooz, I, Scheen, André, Senterre, Jacques
Gestational diabetes, even if it seems to induce far less foetal complications than classical type 1 or type 2 diabetes mellitus, may be deleterious for the child. We will successively consider the...
Scheen, André, Letiexhe, Michel, Lefebvre, Pierre
The present study aimed at investigating the influence of the time interval between injection of regular insulin and meal ingestion on postprandial glucose changes and overall blood glucose control...
Severe/extreme obesity: a medical disease requiring a surgical treatment? (1999)
Scheen, André, Luyckx, Françoise, Desaive, Claude, Lefebvre, Pierre
Obesity poses a serious health hazard and its treatment is often disappointing. Surgical approaches have been proposed for treating severe obesity (body mass index or BMI > or = 35 kg/m2) with...
Medical aspects of obesity. (1999)
Scheen, André, Luyckx, Françoise
Obesity poses a serious health hazard and its treatment is often disappointing. Major advances have been made during recent years in the understanding of body weight regulation, with the discovery of...
Le diabete gestationnel: physiopathologie et signification pronostique pour la mere. (1999)
Geronooz, I, Scheen, André, Lefebvre, Pierre
Pregnancy is associated with important changes in mother metabolism, especially in late gestation, among which a decreased glucose tolerance caused by insulin resistance. In some of these women,...
Le diabete gestationnel: definition, depistage et traitement. (1999)
Geronooz, I, Scheen, André, Foidart, Jacqueline
Defined as glucose intolerance with onset or first recognition during pregnancy, gestational diabetes mellitus represents in fact an heterogeneous clinical entity which may concern 1 to 4% of all...
Medicaments et grossesse. (1999)
Since the dramatic observations of fetal abnormalities associated to thalidomide use during pregnancy, the risk of malformations when prescribing drugs in pregnant women is a well-known problem,...
L'obesite feminine: souci esthetique ou probleme medical? (1999)
Luyckx, Françoise, Scheen, André, Lefebvre, Pierre
Women more and more frequently refer to medical doctors for treating weight excess. Even if the primum movens is usually a pure esthetic concern, medical aspects should not be neglected. Indeed, if...
L'anorexie mentale, une maladie grave specifique de la femme jeune. (1999)
Anorexia nervosa is characterized by a triad comprising anorexia, weight loss, and amenorrhoea. It is typically present in adolescent or young adult women and its prevalence appears to increase in...
Glucose metabolism and the postprandial state. (1999)
Lefebvre, Pierre, Scheen, André
Disturbances of postprandial glucose metabolism are now thought to contribute to cardiovascular disease. Postprandial glucose excursions can be affected by a number of factors, such as the types of...
L'etude clinique du mois. L'etude CAPPP: "The Captopril Prevention Project". (1999)
The Captopril Prevention Project (CAPPP) was a prospective, randomized, open trial which aimed at comparing the prevention by captopril (n = 5492) or by a conventional treatment (n = 5493; diuretics...
Pharma-clinics le medicament du mois. L'orlistat (xenical). (1999)
Scheen, André, Ernest, Philippe, Letiexhe, Michel
Orlistat (tetrahydrolipstatin), launched by Roche under the trade name Xenical, is a selective inhibitor of pancreatic and gastro-intestinal lipases. It reduces the digestion of dietary fat and its...
Pharma-clinics le medicament du mois. Le naratriptan (naramig). (1999)
Naratriptan, launched by Glaxo Wellcome under the trade name Naramig, is a potent and selective agonist of 5-HT1B and 5-HT1D vascular receptors. Available as tablets of 2.5 mg, it is indicated in the...
Comment je traite ... une obesite severe et ses anomalies metaboliques par une gastroplastie. (1999)
Luyckx, Françoise, Scheen, André, Letiexhe, Michel, Desaive, Claude, Gielen, Jean-Louis, Lefebvre, Pierre
Severe obesity, defined as a body mass index > or = 35 kg/m2, is frequently associated with various biological abnormalities, particularly in the presence of intra-abdominal adiposity. The most...
Comment j'explore ... le risque coronarien individuel extrapole a 10 ans. (1999)
Scheen, André, Rorive, Georges, Kulbertus, Henri
The European Societies of Cardiology. Atherosclerosis and Hypertension agreed upon a table allowing to evaluate the coronary risk after 10 years according to five parameters (sex, age, smoking, total...
L' "epidemie" des maladies metaboliques, un probleme majeur de sante publique. (1999)
The industrialized world is confronted to a real epidemic of metabolic diseases triggered by overeating and sedentarity. Obesity, hypercholesterolaemia, diabetes mellitus and the metabolic syndrome...
Pharmacological treatment of obesity: present status. (1999)
Scheen, André, Lefebvre, Pierre
OBJECTIVE: Obesity poses a serious health hazard and its treatment is often disappointing. This review describes the present status of pharmacological treatment of obesity in man. DESIGN: Obesity...
Pharma-clinics. Le medicament du mois. L'aceclofenac (Biofenac). (1999)
Aceclofenac, a phenylacetic acid derivative, is a new nonsteroidal anti-inflammatory drug (NSAID). It is indicated in the symptomatic treatment of pain and inflammatory or degenerative arthropathies:...
There appears to be a continuum between the cardiovascular risk and the level of blood cholesterol, which hinders the definition of normal values, intervention threshold and therapeutic goals. The...
The LIPID study is a placebo-controlled, double-bind, randomized trial, performed in 9014 patients with coronary heart disease and total cholesterol levels of 155 to 271 mg/dl. After a mean follow-up...
The decision to treat an individual with low HDL cholesterol level depends on his overall cardiovascular risk profile and the therapeutic strategy is based upon the characteristics of the lipid...
Pharma clinics. Comment je traite ... un patient diabetique avec obesite severe. (1998)
Scheen, André, Triches, K, Luyckx, Françoise, Letiexhe, Michel, Lefebvre, Pierre
Obesity plays a crucial role in type 2 diabetes pathophysiology and a major weight loss markedly improves glycaemic control. The common failure of classical treatments leads to the use of more...
Pharma-clinics. Le medicament du mois. Le formoterol (Oxis Turbohaler). (1998)
Formoterol, commercialized by Astra under the trade name Oxis, is a new potent and selective agonist of beta-2 adrenergic receptors, which is used with a specific device (Turbohaler) allowing...
Comment j'explore ... un sujet avec une concentration basse de cholesterol HDL. (1998)
A decrease in plasma HDL cholesterol concentration is considered as a major cardiovascular risk factor and is a prevalent lipid abnormality among patients with coronary heart disease. This condition...
Besides the classical dietary regimen, it is possible to use specific pharmacological approaches, targeted at the intestine, in order to treat some metabolic disorders. Three approaches will be...
La neuropathie diabetique: donnees epidemiologiques et predictives. (1998)
Neuropathy is a classical complication of diabetes mellitus, to the same extent as micro- and macroangiopathy. Diabetic neuropathy can be schematically divided into peripheral neuropathy, especially...
Luyckx, Françoise, Scheen, André, Proenza, A M, Strosberg, A D, Lefebvre, Pierre, Gielen, Jean-Louis
The postprandial state and risk of cardiovascular disease. (1998)
Lefebvre, Pierre, Scheen, André
Metabolism in man is regulated by complex hormonal signals and substrate interactions, and for many years the clinical focus has centred on the metabolic and hormonal picture after an overnight fast....
Premelle, commercialised by Wyeth-Lederle, is a combination of conjugated estrogens 0.625 mg and medroxyprogesterone acetate 5 mg which is indicated in the treatment of menopause-associated problems,...
Implications virales dans l'etiopathogenie du diabete de type 1: donnees actuelles. (1998)
Radermecker, Régis, Scheen, André, Letiexhe, Michel, Lefebvre, Pierre, De Mol, Patrick
Type 1 diabetes mellitus results from autoimmune destruction of pancreatic beta cells. After having described genetic, immunological and metabolic factors, some researchers have hypothezised that...
Info-congres. Les lecons de la "United Kingdom Prospective Diabetes Study". (1998)
Scheen, André, Lefebvre, Pierre
The United Kingdom Prospective Diabetes Study (UKPDS) is the largest study ever performed in the field of diabetes. It has been carried on in more than 5000 patients with newly diagnosed type 2...
Weekers, Laurent, Scheen, André, Godon, J P
The natural history of diabetic renal disease can be divided into different stages according to the degree of albuminuria and the level of glomerular filtration rate (GFR). Assessment of the early...
Actualites therapeutiques 1997-1998 (1). Seconde partie. (1998)
The most important drugs registered and/or launched in Belgium during the last year in the various disciplines of internal medicine will be briefly described. The originality of each molecule as well...
Sport performance depends on the capacity of oxygen transport to the exercising skeletal muscles. Performance may be increased thanks to an haematocrit augmentation, either by training in high...
Weekers, Laurent, Scheen, André, Lefebvre, Pierre
Diabetic nephropathy (DN) appears in about 30% of patients with type 1 diabetes (D1) and 15 to 60% of patients with type 2 diabetes (D2). It is preceded by microalbuminuria. Microalbuminuria is...
Actualites therapeutiques 1997-1998 (1). Premiere partie. (1998)
The most important drugs registered and/or launched in Belgium during the last year in the various disciplines of internal medicine will be briefly described. The originality of each molecule as well...
Luyckx, Françoise, Scheen, André, Desaive, Claude, Dewe, W, Gielen, Jean-Louis, Lefebvre, Pierre
Obesity is a prevalent metabolic disorder associated with high morbidity and mortality rates. Medical treatment rarely succeeds, and bariatric surgery has been proposed as an alternative therapy. The...
Clinical efficacy of acarbose in diabetes mellitus: a critical review of controlled trials. (1998)
Acarbose, an alpha-glucosidase inhibitor, is a new antihyperglycaemic agent which has been proposed as add-on therapy in Type 2 diabetic patients not well-controlled with diet alone, sulphonylurea,...
Traitement ultime du diabete de type 2: insulinotherapie intensive ou chirurgie bariatrique? (1998)
Scheen, André, Paquot, Nicolas, Triches, K, Luyckx, Françoise, Letiexhe, Michel, Lefebvre, Pierre
Pharma-clinics. Le medicament du mois. L'atorvastatine (Lipitor). (1998)
Atorvastatin, commercialized by the pharmaceutical companies Parke-Davis and Pfizer under the trade name Lipitor, is a new statin acting as a potent hypolipidaemic drug. By inhibiting HMG-CoA...
Pharmaco-economie du diabete de type 2. (1998)
Scheen, André, Lefebvre, Pierre
Type 2 diabetes has long been considered as a benign disease, whereas it is in fact associated with an enormous socio-economic cost. The major part of the burden of diabetes results from the...
The demonstration that stains reduce the risk of cardiovascular diseases, in both secondary and primary prevention trials, led to the recent publication of sophisticated pharmaco-economical studies....
Pharma-clinics. Le medicament du mois. L'alendronate (Fosamax). (1998)
Alendronate (Fosamax, Merck Sharp & Dohme) is an aminobisphosphonate which inhibits bone turnover by suppressing the activity of osteoclasts without increasing the risk of osteomalacia. Alendronate...
Le cas clinique du mois. Une nephropathie galopante chez un patient diabetique de type 2. (1998)
Philips, Jean-Christophe, Scheen, André, Firre, E, Robin, M, Cambier, P, Lefebvre, Pierre
We report the case of a patient with insulin-requiring type 2 diabetes who exhibited a rapid deterioration of his renal function leading to haemodialysis in a few months. Various diagnosis were...
Scheen, André, Buxton, O M, Jison, M, Van Reeth, O, Leproult, R, L'Hermite-Baleriaux, M, ...
To study the effects of time of day on neuroendocrine and metabolic responses to exercise, body temperature, plasma glucose, insulin secretion rates (ISR), and plasma cortisol, growth hormone (GH)...
Aggressive weight reduction treatment in the management of type 2 diabetes. (1998)
Most patients with Type 2 diabetes are significantly overweight, and diet-induced weight loss can provide marked improvement in their glycaemic control. As conventional therapy combining diet and...
Comment j'explore... une hypertriglyceridemie. (1998)
The strategy for the diagnosis of hypertriglyceridaemia comprises three successive steps. First, the physician should confirm the biological abnormality by at least one additional blood sample taken...
Type 2 diabetes is an important public health problem because of its high prevalence and morbidity rate which both are associated with a considerable social and human cost. The general practitioner...
Consistent variations in glucose regulation across the 24-hour cycle are present in normal subjects. These diurnal variations are altered in various states of impaired glucose tolerance (aging,...
Pharma-Clinics. Le medicament du mois. La ranitidine bismuth citrate (Pylorid). (1998)
Ranitidine bismuth citrate (Pylorid, Glaxo-Wellcome) is a novel salt of ranitidine which provides a unique combination of properties: inhibition of secretion of gastric acid by competitive antagonism...
Le syndrome X, a la croisee des maladies metaboliques et cardio-vasculaires. (1998)
The relationships between metabolic disorders and cardiovascular diseases are very strong. Hypercholesterolaemia and diabetes mellitus, for instance, are well-known risk factors. The multifaceted...
Pharma-Clinics. Essais cliniques medicamenteux: importance et role du medecin generaliste . (1998)
Clinical trials are an essential step in the development of a drug. They must be conducted according to strict rules called "Good Clinical Practice" or GCP. GCP requirements aim to guarantee a...
Luyckx, Françoise, Desaive, Claude, Thiry, Anne-Marie, Dewe, W, Scheen, André, Gielen, Jean-Louis, ...
OBJECTIVE: To examine the factors associated with liver steatosis in severely obese subjects and to test the potential reversibility of fatty liver after weight loss. DESIGN: Retrospective clinical...
Oral antidiabetic agents. A guide to selection. (1998)
Scheen, André, Lefebvre, Pierre
Type 2 diabetes mellitus (formerly named non-insulin-dependent diabetes mellitus or NIDDM) is a heterogeneous disease resulting from a dynamic interaction between defects in insulin secretion and...
L'erytheme necrolytique migrateur. (1998)
Dandrifosse, J F, Dandrifosse, A C, Pierard, Gérald, Scheen, André, Dandrifosse, Guy
Necrolytic migratory erythema (NME) is generally associated with glucagonoma. It waxes and wanes by successive relapses and remissions. The clinical and microscopical diagnosis is complex. In...
Acute Functional Iron Deficiency in Obese Subjects During a Very-Low-Energy All-Protein Diet (1997)
Beguin, Yves, Grek, Vincent, Weber, Georges, Sautois, Brieuc, Paquot, Nicolas, Pereira, Maguy, ...
We examined whether a very-low-energy all-protein diet (VLED) would produce detectable changes in iron as well as in other trace elements. Twenty-five obese patients consumed for 2 wk a VLED...
Reactivite bronchique chez les patients diabetiques. (1997)
Piéron, Maurice, Scheen, André, Corhay, Jean-Louis, Radermecker, Maurice, Lefebvre, Pierre
The data of the literature concerning bronchial reactivity in diabetic patients are controversial. Therefore, we studied the influence of the presence of a diabetic cardiac autonomic neuropathy (CAN)...
Comment j'explore ... le syndrome d'insulinoresistance grace a ses marqueurs biologiques. (1997)
Luyckx, Françoise, Scheen, André, Gielen, Jean-Louis, Lefebvre, Pierre
Perspective in the treatment of insulin resistance. (1997)
Improving the action of insulin is a relatively new concept in therapy. It should, however, become more and more important because of the rapid expansion of the insulin resistance syndrome (including...
Non-insulin-dependent diabetes mellitus (NIDDM, type 2 diabetes) is a heterogeneous disease resulting from a dynamic interaction between defects in insulin secretion and insulin action. There are...
Overkamp, D, Gautier, J F, Renn, W, Pickert, A, Scheen, André, Schmulling, R M, ...
This study investigated the ability of two models to represent glucose kinetics in the basal steady state and during an intravenous glucose tolerance test (IVGTT). Six young nonobese male subjects...
Non-insulin-dependent diabetes mellitus in the elderly. (1997)
The prevalence of non-insulin-dependent diabetes mellitus dramatically increases with age. Older diabetic subjects have an increased frequency of complications from diabetes compared with their...
Acute functional iron deficiency in obese subjects during a very-low-energy all-protein diet. (1997)
Beguin, Yves, Grek, V, Weber, Géraldine, Sautois, Brieuc, Paquot, Nicolas, Pereira-Martins, Maguy, ...
We examined whether a very-low-energy all-protein diet (VLED) would produce detectable changes in iron as well as in other trace elements. Twenty-five obese patients consumed for 2 wk a VLED...
Letiexhe, Michel, Scheen, André, Lefebvre, Pierre
From a metabolic point of view, anorexia nervosa may be viewed as a mirror image of obesity. We compared insulin secretion, clearance and action on glucose metabolism during an intravenous glucose...
Bozet, Marie-Claire, Gerard, Pascale, Scheen, André, Lefebvre, Pierre, Castillo, M J
Measurement of glycosylated haemoglobin has become an essential tool in the management of diabetic patients. A recently developed device allows the rapid immuno-assay of HbA1c in 1 microliter...
Gorus, F K, Goubert, P, Semakula, C, Van De Walle, Claude, De Schepper, J, Scheen, André, ...
IA-2 has been identified as an autoantigen that is recognized by immunoglobulins from insulin-dependent diabetic (IDDM) patients. Using a liquid phase radiobinding assay, we performed an...
Paquot, Nicolas, Schneiter, P, Jequier, E, Gaillard, R, Lefebvre, P J, Scheen, André, ...
Increased endogenous glucose production (EGP) and gluconeogenesis contribute to the pathogenesis of hyperglycaemia in non-insulin-dependent diabetes mellitus (NIDDM). In healthy subjects, however,...
Scheen, André, Castillo, M J, Lefebvre, Pierre
Defective insulin secretion plays a crucial role in insulin-dependent (Type 1) and non-insulin-dependent (Type 2) diabetes mellitus as well as in many secondary forms of the disease. Glucagon is a...
Mise au point medicale avant gastroplastie: indications et contre-indications. (1996)
Because of the common failure of the various medical procedures used for the treatment of morbid obesity, surgeons have searched alternatives among which gastroplasty appears to offer now the best...
Changes in breath 13CO2/12CO2 during exercise of different intensities. (1996)
Gautier, J F, Pirnay, Freddy, Lacroix, M, Mosora, F, Scheen, André, Cathelineau, G, ...
The measurement of breath 13CO2/12CO2 is commonly used during exercise to evaluate the oxidation rate of exogenous carbohydrates enriched in 13C. The aim of this study was to investigate whether...
Relationships between sleep quality and glucose regulation in normal humans. (1996)
Scheen, André, Byrne, M M, Plat, L, Leproult, R, Van Cauter, E
To define the effects of sleep on glucose regulation, we analyzed plasma glucose levels, insulin secretion rates (ISR), and plasma growth hormone and cortisol levels in normal subjects receiving a...
Usefulness of fluoxetine in obese non-insulin-dependent diabetics: a multicenter study. (1996)
Daubresse, J C, Kolanowski, J, Krzentowski, G, Kutnowski, M, Scheen, André, Van Gaal, L
Weight reduction is essential in the management of most non-insulin-dependent diabetics, but this therapeutical goal is difficult to obtain. In this double-blind parallel study, 82...
Clinical pharmacokinetics of metformin. (1996)
The biguanide metformin (dimethylbiguanide) is an oral antihyperglycaemic agent widely used in the management of non-insulin-dependent diabetes mellitus (NIDDM). Considerable renewal of interest in...
Paquot, Nicolas, Schneiter, P, Jequier, E, Gaillard, R, Lefebvre, Pierre, Scheen, André, ...
Increased endogenous glucose production (EGP) and gluconeogenesis contribute to the pathogenesis of hyperglycaemia in non-insulin-dependent diabetes mellitus (NIDDM). In healthy subjects, however,...
Alterations in the ultradian oscillations of insulin secretion and plasma glucose in aging. (1996)
Scheen, André, Sturis, J, Polonsky, K S, Van Cauter, E
Normal insulin secretion includes oscillations with a period length of 80-150 min which are tightly coupled to glucose oscillations of similar period. To determine whether normal aging is associated...
Castillo, M J, Scheen, André, Lefebvre, Pierre
This study aims at investigating the influence of the prevailing blood glucose level on the metabolic deterioration that follows a nocturnal interruption of a continuous sc insulin infusion (CSII)....
Scheen, André, Lefebvre, Pierre
Insulin action is crucial for the regulation of glucose metabolism. Insulin plays a key role in suppressing endogenous glucose production by the liver, both in fasting and postprandial states....
Le diabete non insulinodependant: de la physiopathologie au traitement. (1996)
Scheen, André, Lefebvre, Pierre
Non-insulin-dependent (or type 2) diabetes mellitus is a common, underdiagnosed and growing disease in our society. It is responsible for increased morbidity and mortality and represents an important...
Castillo, M J, Scheen, André, Paolisso, G, Lefebvre, Pierre
AIMS: To investigate the hyperglycemic and insulinemic response to repeated glucagon injections in Type-2 (non-insulin-dependent) diabetic patients. METHODS: In overnight fasted Type-2 diabetic...
Bozet, Marie-Claire, Scheen, André, Gerard, Pascale, Castillo, M J, Lefebvre, Pierre
The files of 132 patients with Type 2 diabetes were retrospectively studied to characterize the influence of metabolic control and residual insulin secretion on neuropathy and retinopathy, the two...
Scheen, André, Letiexhe, Michel, Lefebvre, Pierre
In a double-blind, randomized, cross-over study, the metabolic effects of a short treatment with metformin (2 x 850 mg day-1 for 2 days and 850 mg 1 h before evaluation) were compared to those of...
Exogenous glucose oxidation during exercise in relation to the power output. (1995)
Pirnay, Freddy, Scheen, André, Gautier, J F, Lacroix, M, Mosora, F, Lefebvre, Pierre
In order to study the influence of the power output on the oxidation rate of exogenous glucose and on the contribution of the various substrates to the energy demand, we combined the use of...
Glucose metabolism in obese subjects: lessons from OGTT, IVGTT and clamp studies. (1995)
Scheen, André, Paquot, Nicolas, Letiexhe, Michel, Paolisso, G, Castillo, M J, Lefebvre, Pierre
Impaired glucose tolerance and overt diabetes are more frequent in presence than in absence of obesity. In obese subjects, glucose tolerance can be maintained within the normal range by compensating...
Improving the action of insulin. (1995)
Lefebvre, Pierre, Scheen, André
Improving the action of insulin is a relatively new concept in diabetes management. Insulin sensitivity can be improved by reduction of excessive body weight, regular physical activity and, possibly,...
Sturis, J, Scheen, André, Leproult, R, Polonsky, K S, Van Cauter, E
Under basal and stimulated conditions, normal insulin secretion oscillates with periods in the ultradian 100-150-min range. To test the hypothesis that oscillatory insulin delivery is more efficient...
Castillo, M J, Scheen, André, Lefebvre, Pierre
The aim of this study was to describe an adaptation of the glucagon test allowing the simultaneous characterization of insulin secretion and sensitivity. A glucagon test (1 mg/m2) was performed in...
Letiexhe, Michel, Scheen, André, Gerard, Pascale, Desaive, Claude, Lefebvre, Pierre
To study the metabolic effects of normalizing body weight, a frequently sampled iv glucose tolerance test (0.3 g/kg) was performed before [body mass index (BMI), 37.7 +/- 0.5 kg/m2] and 14 +/- 2...
Amylin/islet amyloid polypeptide: biochemistry, physiology, patho-physiology. (1995)
Castillo, M J, Scheen, André, Lefebvre, Pierre
Amylin is a 37 amino-acid peptide mainly produced by the islet beta-cell. Aggregation of amylin is partly responsible for amyloid formation. Amyloid deposits occur both extracellularly and...
Comment explorer la sensibilite a l'insuline chez l'homme? (1995)
Scheen, André, Paquot, Nicolas, Letiexhe, Michel, Castillo, M J, Lefebvre, Pierre
The two most widely used methods for studying insulin sensitivity in man are the euglycaemic hyperinsulinaemic clamp and the intravenous glucose tolerance test with minimal model assessment. The...
Antihyperglycaemic agents. Drug interactions of clinical importance. (1995)
Scheen, André, Lefebvre, Pierre
Non-insulin-dependent (type 2) diabetes mellitus (NIDDM) affects middle-aged or elderly people who frequently have several other concomitant diseases, especially obesity, hypertension,...
Glucose handling, diabetes and ageing. (1995)
Paolisso, G, Scheen, André, Lefebvre, Pierre
The relationship between ageing and glucose homeostasis is still an open debate. In fact, the mechanisms by which glucose metabolism is progressively impaired with increasing age are not completely...
Van Cauter, E V, Polonsky, K S, Blackman, J D, Roland, D, Sturis, J, Byrne, M M, ...
To define the chronobiology of glucose tolerance and insulin secretion in obesity, nine obese men and nine lean men were studied during constant glucose infusion for 53 h, including 8 h of nocturnal...
The use of acarbose in the prevention and treatment of hypoglycaemia. (1994)
Lefebvre, Pierre, Scheen, André
This paper reviews the use of acarbose in the prevention and treatment of hypoglycaemia. In diet- or sulfonylurea-treated patients, acarbose may reduce the incidence of late postprandial...
Scheen, André, De Magalhaes, A C, Salvatore, T, Lefebvre, Pierre
In a double-blind cross-over study, we investigated a possible influence of the alpha-glucosidase inhibitor acarbose on the bioavailability of the biguanide compound metformin. Each of the six...
Therapy for obesity--today and tomorrow. (1994)
Scheen, André, Desaive, Claude, Lefebvre, Pierre
Obesity poses a serious health hazard and its treatment is often disappointing. Besides conservative methods, the place of pharmacotherapy, very-low-calorie diets, and even, in selected cases,...
Duysinx, Bernard, Scheen, André, Gerard, Pascale, Letiexhe, Michel, Paquot, Nicolas, Lefebvre, Pierre
This study aimed at testing whether 12 rather than 26 plasma glucose and insulin determinations can be used to calculate the indices of insulin sensitivity and of glucose effectiveness using...
Paolisso, G, Scheen, André, Cozzolino, D, Di Maro, G, Varricchio, M, D'Onofrio, F, ...
The aim of the present study was to investigate the effects of magnesium supplementation on glucose uptake and substrate oxidation in noninsulin-dependent (type II) diabetic patients. Nine elderly...
Letiexhe, Michel, Scheen, André, Gerard, Pascale, Desaive, Claude, Lefebvre, Pierre
This study investigated the effects of a drastic weight reduction on insulin secretion rate (ISR), insulin metabolic clearance rate (MCRI) and insulin sensitivity (SI) in severely obese subjects. A...
Castillo, M J, Scheen, André, Lefebvre, Pierre
The metabolic clearance rate of insulin (MCRI) in 10 non-obese type 2 diabetic patients treated with either insulin alone or combined insulin plus sulfonylurea therapy is investigated. A classical...
Detection of early sympathetic cardiovascular neuropathy by squatting test in NIDDM. (1994)
Marfella, R, Salvatore, T, Giugliano, D, Di Maro, G, Giunta, R, Torella, R, ...
OBJECTIVE--To determine the role of the squatting test in the detection of early sympathetic neuropathy in patients with non-insulin-dependent diabetes mellitus (NIDDM). RESEARCH DESIGN AND...
Castillo, M J, Scheen, André, Jandrain, Bernard, Lefebvre, Pierre
Changes in the metabolic clearance rate of insulin (MCRI) have been described in several pathological conditions. Conflicting data suggest that they may be related to either body mass index (BMI) or...
Magnesium et metabolisme glucidique. (1994)
Lefebvre, Pierre, Paolisso, G, Scheen, André
The interrelationships between magnesium and carbohydrate metabolism have regained considerable interest over the last few years. Insulin secretion requires magnesium: magnesium deficiency results in...
Gautier, J F, Pirnay, Freddy, Jandrain, Bernard, Lacroix, M, Mosora, F, Scheen, André, ...
This study investigated the percentage of carbohydrate utilization than can be accounted for by glucose ingested during exercise performed after the ingestion of the potent lipolysis inhibitor...
Cano, M D, Gonzalvo, C, Scheen, André, Castillo, M J
The clinical evaluation of apolipoproteins is of interest in order to characterize the risk profile for ischemic heart disease both in normolipidemic and hyperlipidemic subjects. In the...
Insulin secretion, clearance, and action on glucose metabolism in cirrhotic patients. (1993)
Letiexhe, Michel, Scheen, André, Gerard, Pascale, Bastens, B H, Pirotte, Jeannine, Belaiche, Jacques, ...
To study the mechanisms of glucose intolerance and hyperinsulinism in liver cirrhosis, we compared the plasma glucose, insulin, and C-peptide levels during a frequently sampled i.v. glucose tolerance...
Pharmacological treatment of the obese diabetic patient. (1993)
Scheen, André, Lefebvre, Pierre
Obesity is a well-known risk factor for non-insulin-dependent (or Type 2) diabetes mellitus. Consequently, reduction of weight excess comes to the front line in the prevention and management of...
Jandrain, Bernard, Pallikarakis, N, Normand, S, Pirnay, Freddy, Lacroix, M, Mosora, F, ...
The aim of the present study was to compare the metabolic fate of repeated doses of fructose or glucose ingested every 30 min during long-duration moderate-intensity exercise in men. Healthy...
Scheen, André, Jandrain, Bernard, Humblet, Dominique, Jaminet, C B, Gaspard, Ulysse, Lefebvre, Pierre
OBJECTIVE: To study the effects of the slightly estrogen-dominant monophasic low-dose oral contraceptive (OC) Diane-35 (Schering AG, Berlin, Germany) (35 micrograms ethinyl estradiol [EE2] + 2 mg...
Hyperlipidemies et medicaments hypolipidemiants. (1993)
Scheen, André, Paquot, Nicolas
Hyperlipidaemia, as a primary atherogenic risk factor, represents a major problem of public health. This review first reminds the main steps of lipoprotein metabolism, the classification of the most...
Endogenous substrate oxidation during exercise and variations in breath 13CO2/12CO2. (1993)
Gautier, J F, Pirnay, Freddy, Jandrain, Bernard, Lacroix, M, Mosora, F, Scheen, André, ...
This study attempted to induce a major shift in the utilization of endogenous substrates during exercise in men by the use of a potent inhibitor of adipose tissue lipolysis, Acipimox, and to see to...
Scheen, André, Castillo, M J, Lefebvre, Pierre
Non-insulin-dependent diabetes mellitus (NIDDM) appears to be an heterogeneous disorder characterized by both relative insulin deficiency and impaired insulin action. The initial management of NIDDM...
Fluoxetine therapy in obese diabetic and glucose intolerant patients. (1992)
Kutnowski, M, Daubresse, J C, Friedman, H, Kolanowski, J, Krzentowski, G, Scheen, André, ...
A double-blind placebo-controlled trial was conducted, involving 97 obese diabetic and glucose intolerant patients receiving either 60 mg fluoxetine daily (47 patients) or a placebo (50 patients); a...
Paolisso, G, Sgambato, S, Varricchio, M, Scheen, André, D'Onofrio, F, Lefebvre, Pierre
OBJECTIVES: This study aimed at investigating the effects of pulsatile and continuous insulin delivery on glucose kinetics in non-insulin-dependent (type 2) diabetic patients with secondary failure...
Moutschen, Michel, Scheen, André, Lefebvre, Pierre
The reasons why diabetic patients present with an increased susceptibility to frequent and protracted infections remain unclear. The virtual absence of epidemiological studies of the independent risk...
Devices for the treatment of diabetes: today. (1992)
Although single or multiple daily subcutaneous injections of insulin with syringes are the mainstay of insulin delivery techniques for the treatment of diabetes mellitus, several other methods are...
From obesity to type 2 diabetes. (1992)
Obesity is a well-known risk factor for the development of non-insulin-dependent diabetes mellitus (NIDDM). Both insulin resistance and concomitant B-cell dysfunction are necessary for the...
Assessment of insulin resistance in vivo: application to the study of type 2 diabetes. (1992)
Scheen, André, Lefebvre, Pierre
Besides insulin secretion, insulin sensitivity plays a key role in the feedback glucose-insulin closed loop. It can be altered in numerous physiological, pathological and pharmacological conditions....
Management of non-insulin-dependent diabetes mellitus. (1992)
Lefebvre, Pierre, Scheen, André
The initial management of non-insulin-dependent diabetes mellitus (NIDDM) should include patient education, dietary counselling and, when feasible, individualised physical activity. It is only when...
Scheen, André, Camus, G, Fossion, Anny
The effects of beta-adrenergic blockade on the exercise-induced hyperlactatemia (Lap) have been studied in 31 adult male subjects [age: 25 +/- 1 years; body weight: 69 +/- 1 kg; VO2max: 54 +/- 1 ml...
Scheen, André, Camus, G, Fossion, A
The effects of beta-adrenergic blockade on the exercise-induced hyperlactatemia (Lap) have been studied in 31 adult male subjects [age: 25 +/- 1 years; body weight: 69 +/- 1 kg; VO2max: 54 +/- 1 ml...
Lilet, Henri, Krzentowski, G, Bodson, Arthur, Scheen, André, Lefebvre, Pierre
Our study is based on two constatations: 1) Hyperinsulinaemia, a possible atherogenic factor, is frequent under continuous subcutaneous insulin infusion. 2) Pulsatile intravenous insulin delivery...
Scheen, André, Paolisso, G, Salvatore, T, Lefebvre, Pierre
OBJECTIVE: To study the short-term effects of the serotoninergic anorectic drug d-fenfluramine on insulin-induced glucose disposal. RESEARCH DESIGN AND METHODS: A randomized double-blind...
Paolisso, G, Scheen, André, Giugliano, D, Sgambato, S, Albert, Adelin, Varricchio, M, ...
The aim of this study was to see if the greater effect of insulin on hepatic glucose output when insulin is given using 13-min pulses in man remains when the same amount of insulin is delivered using...
Alimentation avant, pendant et après l'exercice physique chez le sujet normal et diabétique (1990)
Jandrain, Bernard, Lefèbvre, Pierre, Pirnay, Freddy, Scheen, André
Magnesium and glucose homeostasis. (1990)
Paolisso, G, Scheen, André, D'Onofrio, F, Lefebvre, Pierre
Magnesium is an important ion in all living cells being a cofactor of many enzymes, especially those utilising high energy phosphate bounds. The relationship between insulin and magnesium has been...
Jandrain, Bernard, Humblet, Dominique, Jaminet, C B, Scheen, André, Gaspard, Ulysse, Lefebvre, Pierre
To investigate the effects of two slightly estrogen-dominant, monophasic, low-dose oral contraceptives on carbohydrate metabolism, 40 healthy young women were randomly allocated to receive either 30...
Paolisso, G, Buonocore, S, Gentile, S, Sgambato, S, Varricchio, M, Scheen, André, ...
The present study aimed at investigating the hyperglycaemic, lipolytic and ketogenic effects of small doses of glucagon delivered continuously or in a pulsatile manner. The study was performed in...
Effects of pulsatile delivery of insulin and glucagon in humans. (1989)
Paolisso, G, Scheen, André, Albert, Adelin, Lefebvre, Pierre
The purpose of the present study was to investigate the respective effects of continuous intravenous delivery of both insulin and glucagon compared with those of pulsatile insulin (and continuous...
Scheen, André, Gillet, Jérémie, Rosenthaler, J, Guiot, J, Henrivaux, P, Jandrain, Bernard, ...
With the aim of assessing a new somatostatin analogue to prevent the metabolic changes induced by a 6-h nocturnal arrest of an insulin pump, nine C-peptide negative Type 1 (insulin-dependent)...
Effect of osmolality on availability of glucose ingested during prolonged exercise in humans. (1989)
Jandrain, Bernard, Pirnay, Freddy, Lacroix, M, Mosora, F, Scheen, André, Lefebvre, Pierre
The aim of this study was to investigate whether the osmolality of a glucose solution, ingested at the beginning of a prolonged exercise bout, affects exogenous glucose disposal. We investigated the...
Scheen, André, Lefebvre, Pierre
According to the modern pathophysiological understanding of type 2 diabetes and the mechanisms of sulfonylurea action, combined insulin-sulfonylurea therapy appears to be an interesting alternative...
Continuous subcutaneous insulin infusion is characterized by a basal insulin delivery rate to which insulin boluses are added. The basal delivery rate maintains a small insulin reserve in the local...
Castillo, M J, Scheen, André, Gualda, P, Lefebvre, Pierre
In eight insulin dependent diabetic patients treated by continuous subcutaneous insulin infusion (1.1 +/- 0.2 U/h), the levels (measured hourly from 23 h to 05 h) of blood glucose, non esterified...
Adaptations au sport du diabétique traité par insuline (1988)
Jandrain, Bernard, Pirnay, Freddy, Scheen, André, Lefebvre, P J
Performing muscular exercise regularly is generally recommended to diabetics; indeed, exercise increases muscle insulin sensitivity, helps fighting overweight and, at least partly, tends to correct...
Prostaglandines, secretion d'insuline et diabete sucre. (1988)
Giugliano, D, Torella, R, Scheen, André, Lefebvre, Pierre, D'Onofrio, F
The islets of Langerhans have the enzymatic equipment permitting the synthesis of the metabolites of arachidonic acid: cyclo-oxygenase and lipo-oxygenase. Numerous studies have shown that...
Paolisso, G, Sgambato, S, Giugliano, D, Torella, R, Varricchio, M, Scheen, André, ...
Plasma and erythrocyte magnesium levels were measured by atomic absorption spectrometry in 12 healthy subjects and 12 moderately obese patients with Type 2 (non-insulin-dependent) diabetes mellitus....
Insulin sensitivity in anorexia nervosa: a mirror image of obesity? (1988)
Scheen, André, Castillo, M, Lefebvre, Pierre
Although, in many respects and from a metabolic point of view, obesity and AN are clearly two opposite pathological conditions, the available data concerning insulin sensitivity in these two...
Paolisso, G, Sgambato, S, Torella, R, Varricchio, M, Scheen, André, D'Onofrio, F, ...
The respective modulating effects of continuous and intermittent insulin delivery on pancreatic islet cell function were studied in seven normal men and nine insulin-dependent (type 1) diabetic...
Adaptations au sport du diabetique traite par insuline. (1988)
Jandrain, Bernard, Pirnay, Freddy, Scheen, André, Lefebvre, Pierre
Performing muscular exercise regularly is generally recommended to diabetics; indeed, exercise increases muscle insulin sensitivity, helps fighting overweight and, at least partly, tends to correct...
Dose-response curve for torasemide in healthy volunteers. (1988)
The safety and diuretic activity of torasemide (1-isopropyl-3- ([4-(3-methyl-phenylamino)pyridine]-3-sulfonyl)urea) were investigated in a phase I single-blind clinical study. After a pretreatment...
Paquot, Nicolas, Scheen, André, Franchimont, P, Lefebvre, Pierre
The present study aimed at investigating the metabolic and hormonal consequences of intra-nasal administration of insulin in normal man. Lyophylisated regular porcine insulin (Insuline Ordinaire...
Scheen, André, Paquot, Nicolas, Lefebvre, Pierre
The present review concerns the current possibilities of insulin administration through the oral, rectal or nasal routes. The use of vehicle such as liposomes or various polymers protecting the...
U-100 insulin gives some protection against metabolic deterioration due to CSII interruption. (1987)
Scheen, André, Henrivaux, P, Jandrain, Bernard, Lefebvre, Pierre
We investigated the influence of insulin concentration within the insulin pump on the metabolic and plasma free-insulin changes induced by a 6-h nocturnal interruption of continuous subcutaneous...
Castillo, M, Scheen, André, Paolisso, G, Lefebvre, Pierre
The present study aimed at 1) investigating the effect of a combined insulin + glipizide treatment on the metabolic control (HbA1c levels) and insulin requirements (Biostator assessment) in ten...
Scheen, André, Henrivaux, P, Jandrain, Bernard, Paolisso, G, Lefebvre, Pierre
To evaluate the efficacy of a bolus insulin injection to prevent the metabolic alterations induced by a 2-h nocturnal interruption of a continuous subcutaneous insulin infusion (CSII), nine type I...
Paolisso, G, Giugliano, D, Scheen, André, Franchimont, P, D'Onofrio, F, Lefebvre, Pierre
The present study aimed at evaluating the effect of human beta-endorphin on pancreatic hormone levels and on glucose metabolism in normal subjects. Infusion of 143 nmol/h beta-endorphin in 7 subjects...
Paolisso, G, Sgambato, S, Passariello, N, Scheen, André, D'Onofrio, F, Lefebvre, Pierre
The aim of this study was to investigate the role of plasma glucagon levels on the blood glucose response to intravenous insulin administered continuously or in a pulsatile manner. Six type I...
Scheen, André, Jaminet, C, Luyckx, A S, Lefebvre, Pierre
The pharmacokinetics and pharmacological properties of a new micronized preparation of glibenclamide (HB420, 3.5 mg/tablet) were compared to those of the classical formulation (HB419, 5 mg/tablet) in...
Pulsatile hyperglucagonemia fails to increase hepatic glucose production in normal man. (1987)
Paolisso, G, Scheen, André, Luyckx, A S, Lefebvre, Pierre
To study the metabolic effects of pulsatile glucagon administration, six male volunteers were submitted to a 260-min glucose-controlled glucose intravenous infusion using the Biostator. The...
Paolisso, G, Sgambato, S, Passariello, N, Giugliano, D, Scheen, André, D'Onofrio, F, ...
Plasma and erythrocyte magnesium levels were measured by atomic absorption spectrophotometry in 10 healthy volunteers during an oral glucose tolerance test and during an euglycaemic hyperinsulinaemic...
Insulin oscillations per se do not affect glucose turnover parameters in normal man. (1986)
Paolisso, G, Scheen, André, Verdin, Emeline, Luyckx, A S, Lefebvre, Pierre
To compare the metabolic effects of pulsatile vs. continuous iv insulin infusion, normal men had two glucose-controlled iv glucose infusions using the Biostator for 260 min, during which endogenous...
Luyckx, A S, Daubresse, J C, Jaminet, C, Scheen, André, Lefebvre, Pierre
The levels of circulating IgG-insulin antibodies were determined in two groups of diabetic patients before and at 3-month intervals after starting insulin treatment either with monocomponent porcine...
Scheen, André, Vancrombreucq, J C, Delarge, J, Luyckx, A S
The diuretic effects of torasemide and of furosemide were compared in a double blind cross-over study in 13 patients with stable chronic heart failure. Single doses of 10 mg and 20 mg of torasemide...
Insulin-stimulated glucose disposal is not increased in anorexia nervosa. (1985)
Castillo, M, Scheen, André, Lefebvre, Pierre, Luyckx, A S
Insulin-stimulated glucose disposal was investigated using the euglycemic hyperinsulinemic glucose clamp technique in six women with anorexia nervosa (27.3 +/- 4.9 yr old; weight, 38.8 +/- 6.6 kg)...
Scheen, André, Castillo, M, Jandrain, Bernard, Krzentowski, G, Henrivaux, P, Luyckx, A S, ...
In order to evaluate the metabolic consequences of a 2-h nocturnal interruption of continuous subcutaneous insulin infusion (CSII), seven insulin-dependent diabetic patients without residual insulin...
Scheen, André, Lefebvre, Pierre, Luyckx, A S
Peripheral blood glucose, plasma insulin and C-peptide levels were investigated after giving a standardized breakfast (500 kcal, 60 g carbohydrates) to 10 nonobese Type 2 diabetic patients previously...
Scheen, André, Lemaire, Philippe
Seven healthy male subjects underwent a treadmill incremental work test in control conditions and during an intravenous epinephrine infusion (10 micrograms/min). At all exercise intensities,...
Castillo, M J, Scheen, André, Luyckx, A S, Lefebvre, Pierre
A new method for continuous blood collection using the Biostator is described. Blood is withdrawn through the double lumen catheter by a tube installed in the optional channel of the infusion pump....
Krzentowski, G, Scheen, André, Castillo, M, Luyckx, A S, Lefebvre, Pierre
Interruption of a continuous subcutaneous insulin infusion, most often due to technical problems occurring during the night, is a not uncommon event whose metabolic consequences have received...
Metabolic adaptation to prolonged exercise in severely obese subjects. (1983)
Scheen, André, Pirnay, Freddy, Luyckx, A S, Lefebvre, Pierre
In investigating the metabolic adaptation to prolonged exercise in markedly obese subjects, we compared blood glucose, plasma lactate, free fatty acids, insulin and glucagon concentrations during 3 h...
Scheen, André, Luyckx, A S, Fossion, A, Lefebvre, Pierre
This study aimed at investigating the influence of protein-supplemented fasting (PSF) on the tolerance and the fuel-hormone response to endurance exercise in the severely obese subject. For this...
Scheen, André, Cession-Fossion, A, Scheen, Myriam, Luyckx, A
The present study aimed at investigating the effects of an epinephrine (EPI) intravenous infusion (10 micrograms/min for 30 min) in normal subjects and in obese patients before and after 13 days of...
Hormonal and metabolic adaptation to protein-supplemented fasting in obese subjects. (1982)
Scheen, André, Luyckx, A S, Scheen, Myriam, Lefebvre, Pierre
Thirty hospitalized, severely obese patients (40 +/- 2 yr, 82 +/- 4 percent weight excess) were submitted to a 13-d protein-supplemented fast (PSF) with 70 g milk proteins/d (1.26 MJ or 300 kcal)....
Scheen, André, Scheen, Myriam, Juchmes, J
In 9 obese patients, epinephrine infusion (10 microgram/min) did not significantly modify the mean arterial blood pressure (MBP) in basal conditions. This infusion reduced MBP (-7 mm Hg, p less than...
Scheen, André, Cession-Fossion, A, Scheen, Myriam, Luyckx, A
The protein-supplemented fasting induces a progressive but moderate decrease in blood glucose (-26%) and a marked rise in plasma free fatty acids levels (+ 43%). Nevertheless the secretion of...
Luyckx, A S, Guerten, D, Scheen, André, Delporte, Jean-Pierre, Lefebvre, Pierre, Jaminet, F
We have investigated the influence of a single oral administration of indomethacin on blood glucose, plasma free fatty acids (FFA), alpha-amino-nitrogen, insulin and glucagon concentrations in young...
Cardiovascular effects of intravenous tolmesoxide in hypertensive patients. (1981)
Scheen, André, Luyckx, A S, De Graeve, Jean
Tolmesoxide, a potent vasodilating compound, was infused intravenously (0.5 to 3.5 mg/kg b.w., rate of infusion: 2.5 to 10.0 mg/min during 7--25 min, 2 or 3 successive infusions separated by a 30 min...
Critical analysis of the "anaerobic threshold" during exercise at constant workloads. (1981)
Scheen, André, Juchmes, J, Cession-Fossion, A
The method described by Wasserman for anaerobic threshold (AT) determination, based on the recording of ventilatory parameters, was supported by the simultaneous appearance of hyperlactacidemia and...
Scheen, André, Juchmes, J, Cession-Fossion, A, Remacle-Volon, G
During exercises at constant workload, the hyperlactatemia threshold (continuous lactate production during the whole exercise) (48% VO2 max) and the hyperventilation threshold (57% VO2 max) are not...
Endurance apres propranolol chez l'homme effectuant un exercice dynamique general. (1980)
Camus, G, Scheen, André, Cession-Fossion, A, Juchmes, J, Mylle, P, Dreezen, E
The effects of a single oral dose of 40 mg propranolol on endurance time and on the maximum oxygen consumption were studied in eight healthy young men. They were running on a motor-driven treadmill...
Perfusion intraveineuse d'adrenaline et adaptation a l'exercice musculaire chez l'homme. (1979)
Scheen, André, Juchmes, J, Cession-Fossion, A, Volon, G
Eleven normal subjects underwent epinephrine perfusions (1.9; 6.1; 11.8 ng/min) during a short (20 min) and mild (50% VO2 max) exercise. VO2 was not modified by epinephrine perfusion, while heart...
Determinisme de la derive lente de la frequence cardiaque pendant l'exercise musculaire. (1978)
Cornet, Françoise, Scheen, André, Juchmes, J, Cession-Fossion, A
The slow increase in heart rate which is observed in normal man submitted to heavy muscular exercise is due for a part to an activation of orthosympathetic cardiac activity which is blocked by beta...
Diminution de l'hyperventilation d'exercise par le blocage des recepteurs beta-adrenergiques (1976)
Scheen, André, Juchmes, J, Cession-Fossion, A
In normal subjects, beta-adrenergic blockage by propranolol or pindolol reduces exercise hyperventilation (40 to 60% VO2 max).
Scheen, André, Juchmes, J, Lennes, G, Lecomte, Jean
VO2 max, maximum oxygen uptake, has been measured in 4 normal young men, before and after beta-adrenergic blockade (0.5 to 5 mg Pindolol by mouth). Pindolol induces bradycardia and reduces VO2 max. A...
Influence de l'etat d'alimentation sur l'hyperlactacidemie d'exercice (1976)
Scheen, André, Juchmes, J, Cession-Fossion, A M, Volon, G
In normal man, food ingested two hours before the beginning of physical exercise increases the lactacidemia (+ 27%).
Insulin Detemir in the Treatment of Type 1 and Type 2 Diabetes
Philips, Jean-Christophe, Scheen, André
Insulin detemir is a soluble long-acting human insulin analogue at neutral pH with a unique mechanism of action. Following subcutaneous injection, insulin detemir binds to albumin via fatty acid...